<?xml version="1.0"?>
<rdf:RDF
    xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#"
    xmlns:swrlb="http://www.w3.org/2003/11/swrlb#"
    xmlns:swrl="http://www.w3.org/2003/11/swrl#"
    xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
    xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
    xmlns:owl="http://www.w3.org/2002/07/owl#"
    xmlns="http://www.owl-ontologies.com/Ontology1759947724.owl#"
  xml:base="http://www.owl-ontologies.com/Ontology1759947724.owl">
  <owl:Ontology rdf:about=""/>
  <owl:Class rdf:ID="C121214">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation composed of a microRNA 16 (miR-16) mimic, a double-stranded, 23 base pair, synthetic RNA molecule, encapsulated in nonliving bacterial minicells and coated with anti-epidermal growth factor receptor (EGFR) antibodies, with potential antineoplastic activity. Upon intravenous administration and subsequent transfection, nanocell-encapsulated miR-16-based microRNA mimic targets EGFR-expressing tumor cells and facilitates the restoration of expression of the miR-16 family. This leads to the downregulation of the expression of tumor promoting genes and the inhibition of tumor cell growth. In addition, restoration of miR-16 expression sensitizes the tumor cell to certain chemotherapeutic agents. miR-16, a family of microRNAs, is critical to the regulation of gene expression and appears to have a tumor suppressor function; its expression is downregulated in various cancer cell types.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C121214</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:ID="Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C148280">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based metal-organic framework (MOF) compound composed of proprietary X-ray-absorbing metals, with potential radiosensitizing properties. Upon intratumoral administration and subsequent irradiation of the tumor site, RiMO-301 absorbs the X-ray photons and produces reactive oxygen species (ROS), such as hydroxyl radicals and singlet oxygen, which induces ROS-mediated DNA damage in the irradiated cancer cells leading to tumor cell lysis. In addition, RiMO-301 may also contain an as of yet unidentified immunomodulating agent loaded into the channels/pores of the construct that may induce an immune response against the tumor-associated antigens (TAAs) released by the lysed tumor cells, thereby locally killing additional tumor and non-tumor cells. MOFs, porous crystalline materials composed of metal clusters and organic linkers, generate ROS at much lower X-ray dosages than used in standard radiotherapy, which results in reduced radiation exposure and X-ray damage to normal, healthy cells.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C148280</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C62308">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62308</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A small, stable particle whose size is measured in nanometers. These particles are used in various biomedical applications in which they can be utilized as drug carriers or imaging agents. Various targeting agents, such as antibodies, drugs, imaging agents, and reporters can be attached to the surface of a nanoparticle.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C175941">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A polypeptide nanoparticle (PNP)-based small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2), with potential antineoplastic activity. Upon intralesional administration, cotsiranib binds to both TGF-beta 1 and COX-2 messenger RNAs (mRNAs), preventing the translation and expression of TGF-beta 1 and COX-2 proteins. This inhibits TGF-beta 1-mediated signaling and abrogates TGF-beta 1-mediated immunosuppression, which may enhance anti-tumor immunity in the tumor microenvironment (TME) and promote a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. The inhibition of COX-2 prevents COX-2-mediated signaling, which may result in apoptosis and a reduction in tumor cell proliferation, tumor angiogenesis and metastasis.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C175941</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C38140">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C38140</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A synthetic ultrasmall superparamagnetic iron oxide composed of dextran-coated iron oxide nanoparticles (also known as 'ultrasmall particulate iron oxides' or USPIO). Ferumoxtran-10, which accumulates in non-cancerous lymphatic tissue, is used as a molecular resonance imaging (MRI) contrast agent. (NCI04)</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C91087">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A polymeric nanoparticle (PNP) formulation containing the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the PNP formulation may enhance stability and improve delivery.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C91087</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C189803">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A bivalent booster vaccine consisting of elasomeran, a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the prefusion stabilized spike (S) protein of the SARS-CoV-2 Wuhan-Hu-1 strain (original), and imelasomeran, a LNP encapsulating mRNA encoding the prefusion stabilized S-protein of the SARS-CoV-2 Omicron variant B.1.1.529, with potential immunizing activity against SARS-CoV-2. Upon administration of elasomeran/imelasomeran, the LNP binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is then translated by ribosomes to produce the SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C189803</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C201982">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation consisting of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173)-activating, pH-sensitive, polymeric micelles PC7A, loaded with the endogenous STING agonist cGAMP, with potential immunoactivating and antineoplastic activities. Upon intratumoral administration of dual-activating polyvalent STING agonist ONM-501, both the polymer PC7A and the encapsulated cGAMP target and bind to STING, thereby activating the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C201982</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C156926">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C156926</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An mRNA-based, personalized cancer vaccine consisting of a self-amplifying mRNA (SAM), formulated in a lipid nanoparticle (LNP), targeting twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of sapecmeran autogene, the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of APCs. This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. mRNA-based TSNA boosting vaccine is administered after a single dose of the adenoviral tumor-specific neoantigen priming vaccine GRT-C901.  The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C173020">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP) encapsulating messenger RNA (mRNA) encoding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C173020</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C115986">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation containing carbon, with both a mean size of 150 nm, and potential use as a stain for lymph node draining. Upon injection of the carbon nanoparticles at the tumor site, these nanoparticles travel to regional lymph nodes and stain the lymph nodes black due to the presence of the carbon. This may allow for a more precise surgical removal of tumor-draining lymph nodes.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C115986</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C177085">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP) encapsulating a nucleoside modified messenger RNA (modRNA) encoding an optimized form of the full-length severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection of ganulameran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C177085</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C200091">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A technology company headquartered in Newark, Delaware that leverages their Nano-Intelligent Detection/Delivery System for drug delivery; detection of biowarfare agents, chemical warfare agents, and pesticides; immunogenicity tests for biotherapeutics; ELISA assays; nanoparticles for protein extraction or removal; and medical diagnostic kits.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C200091</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C131213">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C131213</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen found on B-lymphocytes, with potential antineoplastic activity. Upon administration of nab-paclitaxel/rituximab nanoparticle AR160, the rituximab moiety specifically binds to CD20 and targets this formulation to CD20-positive tumor cells. Paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of the CD20-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and rituximab-targeting allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets CD20-expressing tumor cells. Rituximab may also induce complement-dependent cytotoxicity and antibody-dependent cellular toxicity.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C187116">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A polymeric nanoparticle formulation of the topoisomerase I inhibitor camptothecin (CPT), an alkaloid isolated from the Chinese tree Camptotheca acuminata, covalently conjugated, via a linker, to a biocompatible polymer scaffold, with potential antineoplastic activity. Upon intravenous administration of polymeric nanoparticle-conjugated CPT DAN-222, the nanoparticles accumulate in tumor tissue and CPT is released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, CPT selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to CPT alone, the nanoparticle formulation has a prolonged half-life and greatly improves the biodistribution of CPT resulting in an accumulation of CPT at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C187116</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C205639">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP) encapsulating self-replicating RNA (srRNA) encoding human interleukin-12 (IL-12), with potential immunomodulatory and antineoplastic activities. Upon intratumoral injection of LNP encapsulated srRNA encoding human IL-12 STX-001, the LNPs bind to the plasma membrane of nearby tumor cells and release srRNA encoding IL-12 into the tumor cells. The srRNA amplifies within the tumor cells, and is translated by the cellular protein translation machinery to produce IL-12, which is secreted into the local tumor microenvironment (TME). The secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, which may enhance immune-mediated destruction of tumor cells and decrease tumor cell proliferation.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C205639</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C88264">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation composed of DOTAP:cholesterol liposome nanoparticles complexed with the plasmid C-VISA BiKDD, with potential antineoplastic activity. C-VISA BikDD: liposome consists of a pancreatic-cancer-specific expression vector VISA (VP16-GAL4-WPRE integrated systemic amplifier) and a pancreatic-cancer-specific promoter CCKAR (cholecystokinin type A receptor) (CCKAR-VISA or C-VISA) which drives expression of the gene BikDD, a mutant form of the potent proapoptotic gene Bik (Bcl-2 interacting killer). Upon administration and transduction into pancreatic tumor cells, expression of BikDD by C-VISA BikDD:liposome may induce pancreatic tumor cell apoptosis and suppress pancreatic tumor cell proliferation. BikDD binds with greater affinity to anti-apoptotic proteins bcl-2, bcl-xl, bcl-w and Mcl-1 and is more potent than wild-type Bik. DOTAP:cholesterol liposome is composed of cationic lipid dioleoyl-trimethylammonium propane (DOTAP) and cholesterol at molar ratio of 1:1.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C88264</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C71696">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C71696</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle albumin-bound formulation of the taxane docetaxel with antineoplastic activity. Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. This nanoparticle albumin-bound formulation solubilizes docetaxel without the use of the nonionic solubilizer Cremophor ELP, permitting the administration of larger doses of docetaxel while avoiding Cremophor ELP-associated toxicity.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C173052">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C173052</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP) encapsulating nucleoside-modified messenger RNA (modRNA) encoding the receptor binding domain (RBD) from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection of abdavomeran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C211533">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C211533</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An orally bioavailable nanoparticle-based formulation containing curcumin, a poorly water-soluble phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties, including antineoplastic, chemopreventive, antioxidant, anti-angiogenic, neuroprotective and anti-inflammatory activities. Upon oral administration, nanocurcumin blocks the formation of reactive-oxygen species (ROS), neutralizes free radicals, and prevents oxidative stress and DNA damage. Curcumin possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation, and inhibits the activity of nuclear factor-kappa B (NF-kB), and the NF-kB-mediated signaling pathway. This decreases the production of inflammatory mediators, such as interferon-gamma (IFNg). It disrupts various cell signal transduction pathways involved in carcinogenesis and prevents the expression of many transcription factors, and modulates the expression of many genes and proteins involved in tumor cell proliferation, invasion and angiogenesis. It also induces tumor cell apoptosis. It may also modulate the immune system, enhance an immune response against tumor cells, and may decrease regulatory T-cells (Tregs). This may prevent and/or inhibit tumor cell formation and proliferation. Compared to the very poorly absorbed curcumin alone, this nanoformulation may have greater bioavailability, an improved pharmacokinetic profile and increased efficacy.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C170743">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A liposomal-based nanoparticle composed of an uncharged P-ethoxy antisense oligodeoxynucleotide (ODN) targeting Bcl-2 mRNA and incorporated in liposomes, with potential antineoplastic activity. Upon administration of liposomal Bcl-2 antisense oligonucleotide BP1002, this agent targets and hybridizes with Bcl-2 mRNA and inhibits the expression of Bcl-2 protein. This may induce tumor cell apoptosis of Bcl2-overexpressing tumor cells and may decrease tumor cell proliferation. Bcl2, a protein involved in regulating programmed cell death, is overexpressed in a wide variety of tumors. It promotes cellular survival and inhibits apoptosis.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C170743</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C179639">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticles (LNPs) encapsulating nucleoside-modified messenger RNA (mRNA) encoding the endogenous cytokine interleukin-7 (IL-7), with potential immunostimulating activity. Upon administration, ribocytokine IL-7 BNT152 is taken up by cells and the expressed IL-7 targets and binds to the IL-7 receptor (IL7R). The binding of IL-7 to IL7R activates IL7/IL7R-mediated signaling, which activates B- and T- lymphocytes, may improve immune recovery and activation, and may enhance anti-tumor immune responses.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C179639</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C190153">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C190153</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid nanoparticle (LNP)-based formulation consisting of a biscistronic mRNA that encodes two independent epigenomic controllers targeting the proto-oncogene MYC (c-Myc), with potential antineoplastic activity. Upon administration of LNP encapsulated MYC-targeting mRNA-based agent OTX-2002, the lipid formulation promotes the uptake by tumor cells. The biscistronic mRNA is then translated by the cellular protein translation machinery to produce two independent epigenomic controllers consisting of a DNA binding domain and an epigenetic effector protein. The two epigenomic controllers bind to regulatory regions on the MYC insulated genomic domain (IGD), a DNA loop bound by CTCF (CCCTC-binding factor). This downregulates MYC expression pre-transcriptionally, which may inhibit proliferation in susceptible tumor cells. MYC, a proto-oncogene overexpressed in a variety of cancers, plays a role in the regulation of transcription and cell proliferation.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C174128">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A preparation of autologous T-cells targeting several multiple myeloma (MM)-associated antigens, with potential immunomodulating and antineoplastic activities. Peripheral blood mononuclear cells (PBMC) from the patient are collected and ex vivo exposed to nanoparticles that mimic antigen-presenting cells (APCs) loaded with multiple MM-associated antigens, including Wilms' tumor 1 (WT1), CD138 (syndecan-1; SDC1), cancer-testis antigen NY-ESO-1 and CS1 (CD319; CRACC; SLAMF7), and are further enriched and expanded ex-vivo before being re-introduced into the patient. Upon administration, the multi-antigen-directed autologous T-cells NEXI-002 are re-introduced into the patient, where they target and kill tumor cells expressing these antigens.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C174128</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C115104">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, Cyanine 5.5 (Cy5.5) and surrounded by polyethylene glycol (PEG) chains attached to cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides, with potential use as a tumor-selective fluorescent imaging agent. Upon intradermal administration of the fluorescent cRGDY PEG-Cy5.5 C dots, the cRGD moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon intraoperative fluorescence imaging, alphaVbeta3-expressing tumor cells can be visualized and the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking can be assessed. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C115104</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C189804">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C189804</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A bivalent booster vaccine consisting of elasomeran, a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the prefusion stabilized spike (S) protein of the SARS-CoV-2 Wuhan-Hu-1 strain (original), and davesomeran, a LNP encapsulating mRNA encoding the prefusion stabilized S-protein of the SARS-CoV-2 Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5), with potential immunizing activity against SARS-CoV-2. Upon administration of elasomeran/davesomeran, the LNPs bind to the plasma membrane of cells and release the mRNA into the cells. The mRNA is then translated by ribosomes to produce the SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C153425">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A preparation of platinum acetylacetonate supported by sol-gel technology functionalized titania, with potential antineoplastic activity. Upon intravenous administration, the platinum moiety forms complexes with nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links, resulting in apoptosis and cell growth inhibition. Compared to platinum alone, the nanoparticle formulation allows increased delivery of platinum to the tumor site, thereby increasing efficacy while reducing systemic toxicity.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C153425</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C157247">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid nanoparticle encapsulating mRNAs encoding for the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), the pro-inflammatory cytokines interleukin-23 (IL-23) and interleukin-36gamma (IL-36gamma), with potential immunomodulatory and anti-tumor activities. Upon intratumoral (IT) injection of the lipid nanoparticle encapsulated mRNAs encoding human OX40L/IL-23/IL-36gamma mRNA-2752, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNAs into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes against the nearby tumor cells. The co-administration of IL-23 and IL-36gamma further stimulates anti-tumor immune responses. Altogether, this may enhance T-cell mediated anti-tumor immune responses thereby killing of the tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand superfamily, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. IL-36gamma activates innate immune cells and promotes T-helper 1 (Th1) responses, whereas IL-23 has been implicated in Th1/Th17 immunity as well as in the modulation of antigen-presenting cells (APCs).</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C157247</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C179302">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A ferritin-based, nanoparticle vaccine consisting of the Epstein-Barr Virus (EBV) envelop glycoprotein gp350 and a saponin-based adjuvant, with potential immunizing activity against EBV. Upon intramuscular administration of EBV gp350-ferritin nanoparticle vaccine with saponin-based adjuvant, the EBV gp350 may activate both humoral and cellular immune responses which may result in protection against EBV infection. EBV, a ubiquitous human herpes virus, is associated with infectious mononucleosis and various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C179302</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C165263">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation consisting of polymeric micelles (PMs), made with poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) block polymers, encapsulating the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with potential antineoplastic activity. Upon intravenous administration of the docetaxel PMs, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site where it binds specifically to the beta-tubulin subunit of the microtubule, thereby stabilizing tubulin and inhibiting microtubule disassembly. This results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C165263</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C162186">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets four of the most commonly occurring KRAS mutations (G12D, G12V, G13D, and G12C), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C162186</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C68566">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C68566</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticles that have been functionalized with chemical amine groups and dextran. These particles have been utilized as magnetic resonance imaging agents and as probes to investivate thrombosis and tumor vasculature in conjunction with a CREKA peptide (cys-arg-glu-lys-ala).</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C2688">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C2688</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C187124">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C187124</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid nanoparticle (LNP) encapsulating nucleoside-modified messenger RNA (mRNA) encoding for bispecific antibody directed against the tumor-associated antigen (TAA) Claudin 6 (CLDN6; CLDN-6) and the human T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, mRNA-encoded anti-CD3/anti-CLDN6 bispecific antibody BNT142 binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is translated and the anti-CD3/anti-CLDN6 bispecific antibody binds to both CD3-expressing T-cells and CLDN6-expressing cancer cells, thereby crosslinking CLDN6-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN6-expressing tumor cells. CLDN6, a transmembrane tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C189806">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A bivalent booster vaccine consisting of tozinameran, lipid nanoparticle (LNP) encapsulating a nucleoside modified messenger RNA (modRNA) encoding an optimized form of the full-length viral spike (S) glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Wuhan-Hu-1 strain (Original), and riltozinameran, a LNP encapsulating a modRNA encoding an optimized form of the full-length viral S protein of the SARS-CoV-2 Omicron variant B.1.1.529, with potential immunizing and anti-COVID-19 activities. Upon injection of riltozinameran/tozinameran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 S protein mRNA into the cells. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C189806</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C96037">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C96037</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based injectable concentrate containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity.  Upon reconstitution and administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Compared to paclitaxel alone, the nanodispersion-based formulation uses less toxic solvents and allows for administration of higher doses resulting in higher concentrations of paclitaxel at the tumor site, and an increased safety profile.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C179620">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding for a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, mRNA-encoded anti-claudin18.2 monoclonal antibody BNT141 binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is then translated by ribosomes to produce the anti-CLDN18.2 monoclonal antibody. The antibody specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells.  CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C179620</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C203653">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C203653</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation consisting of an antigenic acetylcholine receptor (AChR) peptide pool dispersed within a negatively charged polymer matrix of poly(dl-lactide-co-glycolide) (PLGA) particles, with potential immunomodulatory activity. Upon administration, nanoparticle encapsulated AChR epitopes CNP-106 binds to inflammatory cells and delivers multiple AChR epitopes, which initiates tolerogenic immune reprogramming. This may induce and promote antigen-specific tolerance against AChR, which may prevent neuromuscular junction damage and dysfunction that results from autoimmunity targeting AChR.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C180409">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C180409</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A sub-micron spray containing a nanoparticle water soluble equimolar solution composed of delta-9-tetrahydrocannabinol (delta-9-THC; d9-THC), an analogue of tetrahydrocannabinol (THC) and the primary form of THC found in the Cannabis sativa L. plant, and cannabidiol (CBD), a phytocannabinoid derived from Cannabis species, with potential analgesic activity. Upon administration to the oro-buccal membrane, d9-THC/CBD combination agent  binds to and activates the cannabinoid G-protein coupled receptor (CBR) located in the central nervous system (CNS). This activates the inwardly rectifying potassium channels, which decrease presynaptic neuron firing, and inhibits voltage-sensitive calcium channels that decrease neurotransmitter release. This inhibits excitatory postsynaptic neuronal transmission, and inhibits the release of pro-inflammatory mediators. This provides an analgesic effect.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C148522">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C148522</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based cancer vaccine composed of a neutralized bacteriophage Lambda construct that is genetically engineered to contain peptide fragments of human aspartyl/asparaginyl beta-hydroxylase (HAAH; ASPH) on its surface and are fused to the C-terminus of the head protein of phage lambda gpD, with potential immunostimulating and antineoplastic activities. HAAH lambda phage vaccine SNS-301 also contains DNA fragments representing the phage CpG motif that activate the MHC class II pathway. Upon intradermal administration of the HAAH lambda phage vaccine SNS-301, the bacteriophage exposes the immune system to HAAH, producing a HAAH-specific antibody response, and may activate the immune system to induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against HAAH-expressing tumor cells. HAAH is a transmembrane protein and highly conserved enzyme that catalyzes the hydroxylation of aspartyl and asparaginyl residues in epidermal growth factor-like domains of substrate proteins. HAAH is normally expressed in fetal development and is upregulated in a variety of cancer cell types, while its expression is nearly absent in healthy, normal cells. HAAH plays a key role in cancer cell growth, cell motility and invasiveness. Its expression is associated with a poor prognosis.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C160867">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C160867</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle encapsulated messenger RNA (mRNA) encoding human interleukin-12 subunit beta (IL-12B; IL-12 subunit p40) and interleukin-12 subunit alpha (IL-12A; IL-12 subunit p35) with potential immunomodulatory and antineoplastic activities. Although the exact mechanism of action has not been completely characterized, upon intratumoral injection, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the IL-12A and IL-12B mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce a single-chain fusion protein of IL-12B and IL-12A subunits, which is secreted into the local tumor microenvironment (TME). Secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C62311">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >This method entails the attachment of a drug to the surface of nanoparticles. The role of the nanoparticle is to facilitate delivery of the drug to a cellular target that it would not reach in its free form.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62311</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C62367">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An explosive device comprised of carbon nanotubes. These nanoscale devices have desirable optical and thermal properties that can be exploited for novel cancer therapeutics. The ability to manipulate these properties facilitates a controlled, localized activation and clearance mechanism of diseased or abnormal cells.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62367</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C172755">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C172755</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A recombinant, nanoparticle-based vaccine consisting of antigen derived from the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) surface antigen spike (S) protein, with potential immunizing activity against SARS-CoV-2. Upon administration, the SARS-CoV-2 rS nanoparticle vaccine NVX-CoV2373 may induce cell-mediated and antibody mediated immune responses against SARS-CoV-2. This may provide active immunization and protection against SARS-CoV-2 infection.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C91708">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation composed of DOTAP:cholesterol liposomal nanoparticles complexed with a plasmid expression cassette encoding human FUS1 protein, with potential antineoplastic activity. Upon administration, DOTAP:chol-Fus1 liposome complex accumulates mainly in the lungs and particularly in cancer cells. Upon transfer of the Fus1 gene into tumor cells, the expression of Fus1 may induce tumor cell apoptosis and suppress tumor cell proliferation. Fus1, a potent tumor-suppressor protein, is present in normal, healthy cells but often absent in certain cancer cells. DOTAP:cholesterol liposome is composed of cationic lipid dioleoyl-trimethylammonium propane (DOTAP) and cholesterol at a molar ratio of 1:1.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C91708</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C160824">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C160824</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A procedure for the focal treatment of solid tumors. Magnetic nanoparticles of iron oxide are introduced either directly into the tumor or into the resection cavity wall. These particles are subjected to an alternating magnetic field that causes the particles to generate heat and kill the cancer cells by thermal ablation.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C159408">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C159408</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A regimen consisting of atezolizumab and nab-paclitaxel that may be used in the treatment of programmed cell death 1 ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C202248">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) encoding human single-chain interleukin-12 (scIL-12), with potential immunomodulatory and antineoplastic activities. Upon intratumoral injection, the LNP moiety binds to the plasma membrane of nearby cells and releases the scIL-12 mRNA into the cells. The mRNA is then translated by the cellular protein translation machinery to produce scIL-12, which is secreted into the local tumor microenvironment (TME). IL-12 activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C202248</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C82391">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C82391</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid nanoparticle formulation containing two small interfering RNAs (siRNAs) for kinesin spindle protein (KSP) and vascular endothelial growth factor (VEGF) with potential antitumor activity. Upon intravenous administration, the siRNAs in KSP/VEGF siRNAs ALN-VSP02ALN bind to both KSP and VEGF messenger RNAs (mRNAs), preventing translation of KSP and VEGF proteins; this may result in growth inhibition of tumor cells that overexpress KSP and VEGF. VEGF and KSP are upregulated in many tumor cells and play an important role in tumor proliferation and survival.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C148531">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C148531</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel, with potential antineoplastic activity. Paclitaxel is covalently bound to polyethylene glycol (PEG)-based block copolymers which forms a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic paclitaxel. Upon administration of the paclitaxel polymeric micelle formulation NANT-008, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micellar formulation allows the delivery of higher doses of paclitaxel to target tissues while minimizing systemic toxicity.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C117733">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Orally available, nanobubble-based, electrokinetically modified water (EMW) composed of reverse osmosis water where the minerals calcium chloride, magnesium chloride, and potassium bicarbonate have been added and with an increased oxygen concentration compared to normal water. Upon consumption, the EMW may have a beneficial effect on fatigue. This water may protect muscle cells against damage and may improve skeletal muscle function. The water is pretreated with strong, controlled turbulence to create charge-stabilized nanostructures.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C117733</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C62384">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A microscopic vesicle consisting of one or more phospholipid layers surrounding an aqueous core. Liposomes can be utilized to facilitate the delivery of nanoparticles with attached therapeutic agents to biological targets such as specific cells or organs.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62384</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C201245">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C201245</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A sunscreen formulation containing bioadhesive nanoparticles (BNP) encapsulating the broad-spectrum ultraviolet radiation (UVR) protectors avobenzone and octocrylene plus additional naturally-occurring active ingredients, including the flavonoid diosmin, the phenolic phytochemical ferulic acid, the alkaloid cytisine and the polyphenol trans-resveratrol, with potential free radical scavenging, anti-oxidant and skin protective activities. Upon topical application of the BNP-encapsulating avobenzone/octocrylene plus diosmin/ferulic acid/cytisine/trans-resveratrol sunscreen, avobenzone and octocrylene absorb UVR and prevent exposure of the skin to UVR, thereby preventing the formation of UVR-induced reactive oxygen species (ROS). This prevents oxidative damage to DNA, double-stranded DNA breaks and cellular skin damage. The other active ingredients may protect the skin through their ability to scavenge ROS. BNP prevents penetration of the UVR protectors into the skin.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C48415">
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C48415</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A biodegradable poly(ethylene glycol)-poly(D,L-lactide) copolymer micelle nanoparticle-entrapped formulation of paclitaxel with antineoplastic activity. Paclitaxel promotes microtubule assembly and prevents depolymerization, thus interfering with normal mitosis. The copolymer residue increases the water-solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C167334">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C167334</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A pegylated conjugate of SN-38 (7-ethyl-10-hydroxy-camptothecin), a biologically active metabolite of the prodrug irinotecan, with potential antineoplastic activity. Upon administration, the proprietary linker slowly releases SN-38 from the pegylated SN-38 conjugate PLX038. SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. Compared with irinotecan, this formulation allows higher accumulation in solid tumors due to its nanoparticle size and long half-life.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:ID="C88305">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C88305</rdfs:label>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A crosslinked nanoparticle formulation containing quaternary ammonium polyethylenimine (QA-PEI) with potential antibacterial activity. The cationic polymer PEI kills bacteria by rupturing their cell membranes without the development of resistance.  Quaternary ammonium polyethylenimine nanoparticles can be incorporated into dental composite resins or silicon obturator prostheses and may prevent or delay bacterial growth.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C129651">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C129651</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle formulation composed of a polysiloxane-based inorganic matrix bound to cyclic chelates composed of the chelating agent DOTA (1,4,7,10-tetra-azacyclododecane-1-glutaric anhydride-4,7,10-triacetic acid) covalently bound to the paramagnetic contrast enhancer gadolinium (Gd), a high-Z material, with potential use in enhancing diagnostic images upon magnetic resonance imaging (MRI) and potential radiosensitizing activity. Upon intravenous administration of polysiloxane matrix-gadolinium chelates-based nanoparticles, the nanoparticles extravasate to tumor sites due to the unique, hyperpermeable environment of the tumor vasculature. In addition, the small nanoparticles allow for deep penetration into the tumor, where they subsequently accumulate. Upon placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues are enhanced compared to unenhanced MRI. The ultra-small nanoparticles, less than 5 nm in diameter, allow for rapid renal clearance and reduced toxicity. Due to their magnetic properties, these nanoparticles make tumor cells more sensitive to radiation therapy.</rdfs:comment>
    <rdfs:subClassOf>
      <owl:Class rdf:about="#Term"/>
    </rdfs:subClassOf>
  </owl:Class>
  <owl:Class rdf:about="#Term">
    <rdfs:subClassOf>
      <owl:Class rdf:ID="Thing"/>
    </rdfs:subClassOf>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Term</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C180674">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C180674</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticles (LNPs) encapsulating nucleoside-modified messenger RNA (mRNA) encoding the endogenous cytokine interleukin-2 (IL-2), with potential immunostimulating activity. Upon administration, ribocytokine IL-2 BNT153 is taken up by cells and the expressed IL-2 targets and binds to the IL-2 receptor beta subunit (IL2Rb; IL2Rbeta; CD122). The binding of IL-2 to IL2Rb activates IL2Rb-mediated signaling, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction. IL2Rb plays a key role in the proliferation and activation of effector T-cells.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C173055">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP) encapsulating a nucleoside modified messenger RNA (modRNA) encoding an optimized form of the full-length severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection of tozinameran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C173055</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C187021">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A conjugate composed of folic acid analogs and exatecans covalently bound by linkers to the ultrasmall silica-based nanoparticle carrier C'Dot, with potential antineoplastic activity. Upon administration, pasifolate exatecan targets and binds to the human folate receptor 1 (FOLR1; FR-alpha) on FR-alpha-expressing tumor cells. Upon internalization, the camptothecin analog exatecan is released via proteolytic cleavage of the linker and inhibits DNA topoisomerase 1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing FR-alpha. FR-alpha is a high-affinity folate-binding protein and a member of the folate receptor family; it is overexpressed in various cancer cell types.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C187021</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C102875">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C102875</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation of nanoparticles encapsulating the hydrochloride salt form of the anthracycline antibiotic doxorubicin, with potential antitumor activity. Upon intravenous administration, doxorubicin intercalates DNA, interferes with the activity of topoisomerase II, and causes DNA adducts and other DNA damage, resulting in tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C111688">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C111688</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C182103">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C182103</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A vaccine consisting of a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding a full-length version of the spike (S) protein of SARS-CoV-2, with potential immunizing activity against SARS-CoV-2. Upon administration of the LNP-encapsulated SARS-CoV-2 mRNA vaccine PTX-COVID19-B, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is then translated by ribosomes to produce the SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C179638">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticles (LNPs) encapsulating nucleoside-modified messenger RNA (mRNA) encoding the endogenous cytokine interleukin-2 (IL-2), with potential immunostimulating activity. Upon administration, ribocytokine IL-2 BNT153 is taken up by cells and the expressed IL-2 targets and binds to the IL-2 receptor beta subunit (IL2Rb; IL2Rbeta; CD122). The binding of IL-2 to IL2Rb activates IL2Rb-mediated signaling, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction. IL2Rb plays a key role in the proliferation and activation of effector T-cells.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C179638</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C128132">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, Cyanine 5.5 (Cy5.5) and surrounded by polyethylene glycol (PEG) chains attached to cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides labeled with the positron-emitting radioisotope iodine I 124 via a tyrosine linker, with potential use in positron emission tomography (PET)/spiral computed tomography (CT) imaging. Upon intravenous administration of the radiolabeled iodine I 124-cRGDY-PEG-C dots, the cRGD moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon PET/CT imaging, alphaVbeta3 integrin-expressing tumor cells can be visualized and the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking can be assessed. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C128132</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C154569">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A water-soluble, nano-sized formulation composed of nanoparticles encapsulating the poorly water-soluble curcumin, a signal transducer and activator of transcription 3 (Stat3), nuclear factor Kappa B (NF-kB) and poly-tyrosine kinase inhibitor (TKI), and the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of the curcumin/doxorubicin-encapsulating nanoparticle IMX-110, the curcumin moiety targets and inhibits the activation of STAT3 and NF-kB and prevents STAT3- and NF-kB-mediated signaling pathways, both of which are activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, tumor resistance to apoptosis, metastasis and immune evasion. The doxorubicin moiety intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and curcumin, by inhibiting NFkB and STAT3 activity, may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells. Chemotherapeutic agents, such as doxorubicin, upregulate the expression of NF-kB in tumor cells which generates chemotherapy-resistant tumor cells.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C154569</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C131434">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid-based nanoparticle formulation composed of the apoptosis-inducing sphingolipid ceramide encapsulated within nanoliposomes, with potential apoptotic and antineoplastic activities. Upon administration, ceramide nanoliposomes accumulate in the tumor environment, due to the unique properties of the tumor vasculature, and easily enter tumor cells. This delivers ceramide inside the tumor cells, where ceramide induces apoptosis. Although the process is not completely understood, ceramide-dependent apoptosis most likely results from the downregulation of nutrient transporter proteins, which prevents cellular access to extracellular nutrients and causes tumor cell starvation. This selectively destroys tumor cells. Ceramide alone is insoluble and has a very short half-life; therefore, the nanoliposome formulation increases its solubility and half-life. Ceramide plays a key role in the regulation of autophagy, apoptosis, survival and proliferation. Serving as a tumor suppressor lipid, the expression of ceramide is inversely correlated with tumor cell growth, survival and metastasis.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C131434</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C74065">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >The macrolide antibiotic rapamycin bound to nanoparticle albumin with immunosuppressant (see sirolimus) and potential antiangiogenic and antineoplastic activities. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. In turn, inhibition of mTOR may result in the inhibition of the phosphatidylinositol 3 (PI-3) kinase/Akt pathway and vascular endothelial cell growth factor (VEGF) secretion, which may result in decreased tumor cell proliferation and tumor angiogenesis. The binding of water-insoluble rapamycin to nanoparticle albumin permits the albumin-mediated endocytosis of rapamycin by tumor cells and endothelial cells.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C74065</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C173054">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C173054</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP) encapsulating nucleoside-modified messenger RNA (modRNA) encoding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection of SARS-CoV-2 SP modRNA LNP vaccine BNT162a1, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C139003">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based prodrug formulation consisting of polymeric micelles encapsulating the anthracycline epirubicin, with potential antineoplastic activity. Epirubicin is covalently bound to polyethylene glycol (PEG) polyaspartate block copolymers through an acid-labile hydrazone bond and, upon suspension in an aqueous solution, a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic epirubicin is formed. Upon administration of the micellar nanoparticle-encapsulated epirubicin, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, epirubicin is released in the tumor milieu; it then intercalates into DNA and inhibits topoisomerase II, which inhibits DNA replication and interferes with synthesis of both RNA and protein. Compared to the administration of epirubicin alone, this formulation increases the water-solubility of epirubicin and increases its therapeutic effect while decreasing its cardiotoxicity.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C139003</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C166169">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, cyanine 5.5 (Cy5.5), and surrounded by polyethylene glycol (PEG) chains attached to a human prostate-specific membrane antigen (PSMA) inhibitor (PSMAi) and labeled with, via the macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), the radioisotope copper Cu 64, with potential tumor-selective diagnostic properties upon positron emission tomography (PET) imaging. Upon administration of the copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots, the PSMAi moiety selectively targets and binds to PSMA expressed on tumor cells. Upon PET imaging, PSMA-expressing tumor cells can be visualized and assessed. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells. The nanoparticle formulation may allow for enhanced uptake in PSMA-positive tumors.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C166169</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C158083">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C158083</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C185869">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A vaccine consisting of a lipid nanoparticle (LNP) encapsulating four messenger RNAs (mRNAs) encoding the Epstein-Barr Virus (EBV) envelope glycoproteins gp42, gp220, gH and gL, with potential immunizing activity against EBV. Upon intramuscular administration of LNP-encapsulated EBV mRNA vaccine mRNA-1189, the LNP binds to the plasma membrane of cells and releases the mRNAs into the cells. The mRNAs are then translated by ribosomes to produce the EBV envelope glycoproteins. This may activate both humoral and cellular immune responses which may result in protection against EBV infection. EBV, a ubiquitous human herpes virus, is associated with infectious mononucleosis and various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C185869</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C121961">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A polymeric nanoparticle (PNP) formulation containing the poorly water-soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel nanoparticle CPC634, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site, binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C121961</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C62388">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62388</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Self-assembling durable silica spheres that fit inside each other. These spheres range in size from 2 to 50 nanometers and form within seconds. They are small enough to be introduced into the body and have uniform pores that facilitate the controlled release of drugs. The spheres also have the capability to absorb both organic and inorganic substances. For example, nanoparticles can absorb small particles of iron, thereby allowing magnetic control. Thus, the contents of nanospheres can be released upon activation.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C116890">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C116890</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle albumin-bound formulation of a thiocolchicine dimer, an inhibitor of both microtubule and topoisomerase I (TOP1), with antineoplastic and vascular disrupting activities. Upon administration of nanoparticle albumin-bound thiocolchicine dimer nab-5404, this agent binds to tubulin and inhibits its polymerization, which blocks mitotic spindle formation and leads to cell cycle arrest and tumor endothelial cell apoptosis. This disrupts the tumor vasculature and leads to tumor necrosis. In addition, nab-5404 binds to topoisomerase I (TOPI) and inhibits its activity. This results in the inhibition of the repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. The nanoparticle albumin-based formulation permits the albumin-mediated endocytosis of the thiocolchicine dimer by tumor cells and endothelial cells.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C173056">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP) encapsulating a specific form of messenger RNA encoding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection of pidacmeran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C173056</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C62375">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle composed of a metallic shell surrounding a semiconductor. When nanoshells reach a target cancer cell, they can be irradiated with near-infrared light or excited with a magnetic field; either of these exposures will cause the nanoshell to become hot, thereby killing the cancer cell. The metal spheres can absorb or scatter light at several wavelengths, making them well-suited for several clinical applications.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62375</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C131825">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C131825</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation containing a recombinant non-replicating adenovirus (Ad) encoding toll-like receptor 5 (TLR5) and its specific ligand protein 502S, with potential antineoplastic and immunomodulating activities. Upon administration, the Ad preferentially and specifically infects cells expressing the Coxsackievirus and adenovirus receptor (CAR), which is highly expressed in certain human tumors, and expresses both TLR5 and a specific agonistic ligand in the same cell. 502S binds to and activates TLR5, thereby allowing for continuous TLR5 signaling. This stimulates dendritic cells (DCs), monocytes, macrophages and the nuclear factor-kappa B (NF-kappaB) signaling cascade. This activation results in the production of pro-inflammatory cytokines, including interferon alpha, tumor necrosis factor-alpha and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and activate a cytotoxic T-lymphocyte (CTL) response against tumor associated antigens (TAAs). TLR5, a member of the TLR family, plays a key role in the activation of innate immunity.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C62358">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A coordination complex consisting of a gadolinium ion bound to a hexadentate organic chelating agent such as diethylenetriaminepentaacetic acid. Chelates of gadolinium are frequently utilized as magnetic resonance imaging (MRI) contrast agents and can be used to track nanoparticle-mediated drug delivery.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62358</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C147562">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C147562</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A proprietary, biodegradable, poly (lactic-co-glycolic acid) (PLGA) nanoparticle-based formulation composed of synthetic vaccine particles (SVP) encapsulating the macrolide antibiotic rapamycin (SVP-R), with immunosuppressant and drug-protective activities. Upon administration of SVP-R, the SVP moiety is selectively and preferentially taken up through endocytosis by antigen-presenting cells (APCs), located in the spleen and lymph nodes, specifically dendritic cells (DCs). Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, prevents DC maturation, induces tolerogenic DCs, induces regulatory T-cells (Tregs), blocks activation of effector T-cells, induces B-cell tolerance, reduces B-cell activation, and prevents antibody formation, thereby inducing immune tolerance. When co-administered with a biological immunogenic drug known to induce the production of anti-drug antibodies (ADA), SVP-R is able to prevent ADA formation, which prevents the unwanted neutralizing effects of ADAs, increases efficacy of the biological drug, and permits sustained therapeutic activity and repeated administration of the biological drug. In the presence of a specific target antigen, SVP-R is able to prevent an antigen-specific immune response and induces antigen-specific immune tolerance. Compared to the administration of free rapamycin, SVP-R induces long-lasting immunological tolerance.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C157499">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A preparation of self-assembled core-shell nanoscale coordination polymer (NCP) nanoparticles containing an as of yet undisclosed payload with potential immunostimulating and antineoplastic activities. Upon intravenous administration, NCP nanoparticle formulation CPI-100 delivers its payload to tumor cells, which may lead to enhanced immune-mediated killing and regression of tumor cells.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C157499</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C148635">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C148635</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation composed of the poorly water-soluble paclitaxel encapsulated within branched polymers composed of polyethyloxazoline (PEOX), with potential antineoplastic activity. Upon injection of the PEOX-based polymer encapsulated paclitaxel FID-007, the nanoparticles accumulate at the tumor site, due to the unique characteristics of the tumor vasculature, while avoiding normal, healthy tissue. Once the paclitaxel is released, it binds to tubulin inside tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. Compared to the administration of paclitaxel alone, this formulation increases paclitaxel's solubility and enhances its tumor tissue penetration and efficacy, while avoiding systemic exposure, which minimizes its toxicity.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:about="#Thing">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Thing</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C131368">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C131368</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A spherical nucleic acid (SNA) gold nanoparticle formulation composed of small interfering RNAs (siRNAs) targeting the Bcl-2-like protein 12 (BCL2L12) sequence and conjugated to gold nanoparticles, with potential antineoplastic activity. Upon administration of SNA NU-0129, the siRNA prevents the translation of the BCL2L12 gene. Inhibiting the expression of BCL2L12 by NU-0129 induces tumor cell apoptosis. Bcl2L12, a protein belonging to the Bcl-2 protein family, is overexpressed in glioblastoma multiforme (GBM) and plays a role in tumor cell progression and tumor cell resistance to apoptosis. NU-0129 is able to cross the blood brain barrier (BBB).</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C172736">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A vaccine consisting of a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the full-length, prefusion stabilized spike (S) protein of SARS-CoV-2, with potential immunizing activity against SARS-CoV-2. Upon administration of elasomeran, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is then translated by ribosomes to produce the SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C172736</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C190739">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, complexed with danburstotug, a human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential antineoplastic activity. Upon administration of nab-paclitaxel/danburstotug complex AP160, the danburstotug moiety specifically binds to PD-L1 and targets this formulation to PD-L1-positive tumor cells. In turn, paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of PD-L1-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and targeting by the danburstotug moiety allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C190739</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C116792">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C116792</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid nanoparticle (LNP)-based formulation consisting of small-interfering RNAs (siRNAs) directed against transthyretin (TTR) encapsulated in lipids, which has potential use in the treatment of TTR-mediated amyloidosis (ATTR). Upon intravenous administration of patisiran, the lipid formulation promotes the uptake by cells. The siRNAs bind to TTR mRNAs, which may result in the inhibition of both the translation and expression of the TTR protein. ATTR is caused by mutations in the TTR gene and results in the formation of abnormal amyloid proteins that accumulate in and cause damage to various body organs and tissues.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C49178">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C49178</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation composed of a non-viral plasmid DNA vector encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) encapsulated in a biodegradable, biocompatible lipoplex composed of polyethylene glycol (PEG), polyethylenimine (PEI), and cholesterol, with potential immunoactivating and antineoplastic activities. Upon intraperitoneal (IP) delivery of the PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector IMNN-001, the lipoplex is endocytosed by nearby cells, and the plasmid DNA is transported into the nucleus, which leads to local expresssion of IL-12. In turn, the increased IL-12 production at the tumor site activates the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-cell responses against tumor cells.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C198655">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C198655</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A radioconjugate composed of macrophage-targeted polyglucose nanoparticle, labeled with the radioisotope copper Cu 64, with potential use as a tracer for macrophages including tumor-associated macrophages (TAMs) during positron emission tomography (PET). Upon administration of copper Cu 64-labeled macrophage-targeted nanoparticle, the macrophage-targeted nanoparticle is taken up by macrophages, including TAMs in the tumor microenvironment (TME). Upon PET imaging, the macrophages can be detected. The accumulation of macrophages is present in various inflammatory diseases and tumors.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C173879">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An orally bioavailable nanoparticle-based formulation composed of sub-micron particles of the macrolide antibiotic rapamycin incorporated into a pH-sensitive poly(methyl methacrylate) polymer, with potential immunomodulating and antineoplastic activities. Upon oral administration of the encapsulated rapamycin, the nanoparticle specifically delivers rapamycin at the tumor site. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR), a key regulatory kinase. This may suppress mTORC1 activity. In addition, inhibition of mTOR may modulate central memory CD8 T cells, CD3+/CD56+ natural killer (NK) cells and CD8 T-cell responses. This may kill tumor cells. Compared to the administration of rapamycin alone, this formulation improves oral bioavailability of rapamycin with more consistent rapamycin levels, thereby allowing for administration of lower rapamycin dosage, which improves and minimizes rapamycin's toxicity. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C173879</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C121539">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation containing the poorly water-soluble, second-generation taxane analog docetaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel-loaded nanopharmaceutical CRLX301, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, CRLX301 is taken up by the tumor cell via macropinocytosis. Subsequently, docetaxel is slowly released into the cytoplasm where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This prevents mitosis and results in cell death. Compared to the administration of docetaxel alone, this formulation is able to increase docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C121539</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C208344">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation containing an antagomir and oligonucleotide targeting microRNA-10b (miR-10b) encapsulated within a nanoparticle consisting of an iron oxide core that is coated with dextran, with potential antineoplastic activity. Upon administration of microRNA-10b antagomir-iron oxide/dextran-based nanoparticle TTX-MC138, the anti-miR-10b moiety targets and binds to miR-10b inside tumor cells. This inhibits miR-10b and kills miR-10b-overexpressing tumor cells. This may inhibit tumor progression and metastasis. miR-10b, a non-coding RNA that is highly expressed in a variety of metastatic tumor cells, plays a key role in tumor cell migration, invasion and metastasis. The dextran coated iron oxide nanoparticles allow for an increased half-life, decreased clearance and increased tumor cell uptake.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C208344</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C189973">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A bivalent booster vaccine consisting of tozinameran, a lipid nanoparticle (LNP) encapsulating a nucleoside modified messenger RNA (modRNA) encoding an optimized form of the full-length viral spike (S) glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Wuhan-Hu-1 strain (Original), and famtozinameran, a LNP encapsulating a modRNA encoding an optimized form of the full-length viral S protein of the SARS-CoV-2 Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5), with potential immunizing and anti-COVID-19 activities. Upon injection of famtozinameran/tozinameran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 S protein mRNA into the cells. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C189973</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C187083">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C187083</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation composed of a nanoscale coordination polymer (NCP) complex containing two as of yet undisclosed anti-tumor agents, with potential antineoplastic activities. Upon intravenous administration, nanoparticle formulation CPI-300 delivers the anti-tumor agents to tumor cells, which may lead, through as of yet undisclosed mechanism of actions (MoAs), to specific tumor cell killing and inhibition of proliferation of tumor cells.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C137951">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation composed of nanoparticles derived from the human papillomavirus (HPV-NPs) and conjugated to the infrared (IR)-activated fluorescent dye IR700 (IR-700), with potential antineoplastic activity. Upon intravitreal injection of belzupacap sarotalocan, the HPV-NPs target and bind to heparan-sulfated proteoglycans (HSPG) expressed by ocular melanoma cells. Upon irradiation with near-IR (NIR) light, the photosensitizer IR700 becomes activated, generates reactive oxygen species (ROS) and selectively damages the melanoma cell membrane, which induces necrosis of the melanoma cells while sparing the surrounding, healthy non-HSPG-expressing tissue, and potentially preserving vision. HSPGs are overexpressed on a variety of cancer cell types.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C137951</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C178643">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C178643</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation consisting of double core-shell (DUCS) micelles containing 7-ethyl-10-hydroxy-camptothecin (SN-38), the active, hydrophobic metabolite of the prodrug irinotecan, with potential antineoplastic activity. Upon intravenous administration, nanoparticle SN-38-encapsulated micelle formulation SNB-101 diffuses into the tumor site and the SN-38 moiety binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication, and apoptosis. Compared to SN-38 alone, this formulation increases the water solubility of the poorly soluble drug SN-38, and due to the stability of this formulation, it has a much longer circulation time and reduces toxicity to normal, healthy tissues.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C85476">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based prodrug formulation consisting of polymeric micelles incorporating the inorganic platinum agent cisplatin with potential antineoplastic activity. In demplatin pegraglumer, cisplatin forms a polymer-metal complex with hydrophilic polyethylene glycol poly(glutamic acid) block copolymers by attaching to the micelle inner core consisting of the hydrophobic polyamino acids. Upon cell entry and release from the polymer-metal complex, cisplatin forms highly reactive, charged platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-linking, DNA-protein cross-linking and, subsequently, tumor cell apoptosis and growth inhibition. Due to the hydrophilic nature of polyethylene glycol, this formulation increases the water-solubility of cisplatin and decreases the nephrotoxicity and neurotoxicity associated with the administration of cisplatin alone.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C85476</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="SemanticType">
    <rdfs:subClassOf rdf:resource="#Thing"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Los tipos semnticos posibles de los trminos de la ontologa.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >SemanticType</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C166389">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C166389</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A regimen consisting of atezolizumab, carboplatin and nab-paclitaxel that may be used in the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C175469">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An intravenous formulation composed of a phospholipid suspension of nanoparticles containing the synthetic retinoid derivative fenretinide, with potential antineoplastic activity. Upon intravenous administration, fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in susceptible tumor cell types. Fenretinide also binds to and inhibits the activity of mammalian target of rapamycin (mTOR), which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Independent of RAR activation and mTOR inhibition, this agent may also modulate gene expression that leads to ceramide-induced, caspase-independent programmed cell death (PCD) via effectors such as ganglioside GD3 and reactive oxygen species (ROS).</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C175469</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C202862">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel that are coated with the bladder cancer-targeting ligand PLZ4, a cyclic peptide with amino acid sequence of QDGRMGF, with potential antineoplastic activity. Upon administration of the PLZ4-coated paclitaxel-loaded micelle formulation, the PLZ4 moiety specifically targets and binds to bladder cancer cells while avoiding normal, healthy cells. This specifically delivers paclitaxel to bladder cancer cells and, due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micelle formulation and the addition of PLZ4 may allow for the delivery of higher doses of paclitaxel to bladder cancer cells while minimizing systemic toxicity.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C202862</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C173851">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C173851</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A vaccine consisting of a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the full-length spike (S) protein of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), with potential immunizing activity against SARS-CoV-2. Upon intramuscular administration of zorecimeran, the LNP binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is then translated by ribosomes to produce the SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection. S-protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C190751">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C190751</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP) encapsulating a nucleoside modified messenger RNA (modRNA) encoding an optimized form of the full-length viral spike (S) glycoprotein of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5), with potential immunizing and anti-COVID-19 activities. Upon administration of famtozinameran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 S protein mRNA into the cells. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C116869">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation containing pegylated liposomal nanoparticles encapsulating a prodrug of the poorly water-soluble, second-generation taxane analog docetaxel, with potential antineoplastic activity. Upon intravenous administration of the liposomal docetaxel prodrug MNK-010, docetaxel is slowly released into the systemic circulation and accumulates at the tumor site due to the unique characteristics of the tumor's vasculature. In turn, docetaxel is taken up by tumor cells, and subsequently binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and induces cell death. Compared to the administration of docetaxel alone, this formulation is able to increase the delivery of docetaxel into tumors, thereby increasing docetaxel's efficacy while minimizing its toxicity. In addition, this formulation solubilizes docetaxel without the use of toxic solvents, thereby permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C116869</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C184380">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C184380</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A polypeptide nanoparticle (PNP)-based therapeutic comprised of two small interfering RNA (siRNA) oligonucleotides directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-TGF-beta 1/anti-COX-2 siRNAs STP707 binds to both TGF-beta 1 and COX-2 messenger RNAs (mRNAs), preventing the translation and expression of TGF-beta 1 and COX-2 proteins. This inhibits TGF-beta 1-mediated signaling and abrogates TGF-beta 1-mediated immunosuppression, which may enhance anti-tumor immunity in the tumor microenvironment (TME) and promote a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. The inhibition of COX-2 prevents COX-2-mediated signaling, which may result in apoptosis and a reduction in tumor cell proliferation, tumor angiogenesis and metastasis.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C190750">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the full-length, prefusion stabilized spike (S) protein of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5), with potential immunizing activity against SARS-CoV-2. Upon administration of davesomeran, the LNP binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is then translated by ribosomes to produce the SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C190750</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C78450">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A proprietary transferrin receptor-targeted nanoparticle preparation of a non-chemically modified small-interfering RNA (siRNA) directed against the M2 subunit of ribonucleotide reductase (RRM2) with potential antineoplastic activity. Upon administration, transferrin receptor-targeted anti-RRM2 siRNA CALAA-01 binds to transferrin receptors (TfRs), releasing anti-RRM2 siRNA after endocytosis; anti-RRM2 siRNA silences the expression of RRM2 via the RNAi pathway, impeding the assembly of the holoenzyme ribonucleotide reductase (RR) which catalyzes the production of deoxyribonucleotides. As a result, inhibition of cellular proliferation may occur in cells expressing TfR, a cell surface protein overexpressed on various cancer cell types.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C78450</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C66943">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An emulsion containing the tartrate salt of the semisynthetic vinca alkaloid vinorelbine with antineoplastic activity. Vinorelbine binds to tubulin, inhibiting tubulin polymerization into microtubules; cell division is prevented, the cell cycle is arrested metaphase and cell death ensues. In this formulation vinorelbine is emulsified in a homogeneous suspension of nanoparticles, which protects the venous endothelium from coming into direct contact with the active ingredient, potentially reducing vinorelbine-associated venous toxicity at the venous injection site.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C66943</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C162773">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C162773</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A suspension composed of uncoated, stable, submicron particles of the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intra-tumoral administration of the submicron particle paclitaxel sterile suspension, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The submicron particle paclitaxel is produced through a specific proprietary method of submicron particle production without the need for coating agents or carriers and allows for prolonged retention and sustained release at the tumor site.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C150717">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C150717</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A gold nanoparticle (GNP)-based formulation containing panobinostat, a pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon intra-tumoral injection of MTX110, panobinostat is released from the formulation and selectively targets, binds to and inhibits histone deacetylase (HDAC), which induces hyperacetylation of core histone proteins. The accumulation of highly acetylated histones leads to chromatin remodeling, an altered pattern of gene expression, inhibition of tumor oncogene transcription and the selective transcription of tumor suppressor genes. This results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDAC, upregulated in many tumor cell types, is an enzyme family that deacetylates histone proteins. Panobinostat is water insoluble and does not cross the blood-brain barrier (BBB) when administered orally or intravenously. MTX110 solubilizes panobinostat and can be directly injected into the brain, which bypasses the BBB and delivers high concentrations of panobinostat to the tumor, while minimizing systemic toxicity.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C146821">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A topical ointment composed of the water-insoluble taxane paclitaxel that has been processed to form uncoated nanoparticles, with potential antineoplastic activity. Upon topical administration of nanoparticle paclitaxel ointment SOR007 to the affected area, and following epithelial and dermal penetration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The nanoparticles in the nanoparticle paclitaxel ointment are produced through a specific proprietary submicron particle production.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C146821</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C179685">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation composed of a non-viral plasmid DNA vector encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) and a retinoic acid-inducible gene I protein (RIG-I; DDX58) activating moiety encapsulated in dually derivatized chitosan (DDX) nanoparticles, with potential immunostimulating and antineoplastic activities. Upon intravesical administration of detalimogene voraplasmid, the DDX nanoparticles deliver the IL-12 and RIG-I activating DNA plasmid to the bladder urothelium. This leads to local expression of IL-12 and a RIG-I activating moiety. The increased IL-12 production at the tumor site activates the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-lymphocyte (CTL) responses against tumor cells. The RIG-I activating moiety activates the cytosolic RNA receptor RIG-I and induces RIG-I-mediated signaling. This upregulates interferon-alpha (IFN-a) and beta (IFN-b), and induces a potent IFN-mediated innate immune response against the tumor cells. This further induces the activation of NKs and CTLs and induces apoptosis in cancer cells.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C179685</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C136981">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C136981</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation containing nanoparticles composed of liposomes that are conjugated to scFv antibody fragments directed against the ephrin receptor A2 (EphA2; Ephrin A2) and a proprietary prodrug of docetaxel, a poorly water-soluble, second-generation taxane analog, with potential antineoplastic activity. Upon intravenous administration of the anti-EphA2 antibody-directed liposomal docetaxel prodrug MM-310, the anti-EphA2 moiety selectively targets and binds to cells expressing EphI3:I12A2. Following accumulation of MM-310, docetaxel is slowly released from MM-310 and accumulates at the tumor site due to the unique characteristics of the tumor vasculature. In turn, docetaxel is taken up by tumor cells, where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and the induction of cell death. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth; its expression is associated with poor prognosis. Compared to free docetaxel, MM-310 increases docetaxel's half-life, and provides enhanced and specific accumulation in EphA2-expressing tumors, thereby increasing docetaxel's efficacy while lowering its systemic toxicity.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C91074">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C91074</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle formulation containing N-glutaryl phosphatidylethanolamine (NGPE)-liposomes encapsulating oxaliplatin and conjugated to the human transferrin (Tf) ligand, with potential antineoplastic activity. Upon infusion of oxaliplatin-encapsulated transferrin-conjugated NGPE liposomes, the transferrin moiety targets and binds to the Tf receptor, which is overexpressed on a variety of human cancer cells. Upon binding and internalization, oxaliplatin is released and its active derivatives alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which results in an inhibition of DNA replication and transcription. By extending the circulation time and specifically targeting transferrin receptors, this formulation may improve the efficacy and safety of oxaliplatin therapy, compared to administration of oxaliplatin alone. NGPE, a reactive phospholipid, is used as a linker to attach the Tf ligand, to the liposome.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C90534">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C90534</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation containing protein-stabilized liposome nanoparticles encapsulating the poorly water-soluble, second-generation taxane analog docetaxel with antineoplastic activity. Docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Compared to the use of toxic carriers to increase solubilization of docetaxel, protein-stabilized liposomal docetaxel improves drug solubility while avoiding carrier-associated toxicity.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C190391">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP) encapsulating self-replicating RNA (srRNA) encoding human interleukin-12 (IL-12), with potential immunomodulatory and antineoplastic activities. Upon intratumoral injection of LNP encapsulated srRNA encoding human IL-12 JCXH-211, the LNPs bind to the plasma membrane of nearby tumor cells and release srRNA encoding IL-12 into the tumor cells. The srRNA amplifies within the tumor cells, and is translated by the cellular protein translation machinery to produce IL-12, which is secreted into the local tumor microenvironment (TME). The secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, which may enhance immune-mediated destruction of tumor cells and decrease tumor cell proliferation. In addition, the virus-based RNA replicon may trigger anti-viral innate immune responses, further killing tumor cells.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C190391</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C39438">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C39438</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >The Jonsson Comprehensive Cancer Center conducts basic, clinical, and cancer prevention research, while providing the latest treatments to patients, while training the next generation of medical researchers. The Center is developing new technologies for early detection and classification of cancers, combining nanotechnology, systems biology, and molecular imaging. It is affiliated with University of California, Los Angeles and was designated as an NCI comprehensive cancer center in 1974.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C62538">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle delivery system for recombinant human tumor necrosis factor (TNF) consisting of recombinant TNF bound to pegylated colloidal gold nanoparticles with potential antineoplastic activity. Upon intravenous administration, colloidal gold-bound recombinant human TNF travels through the bloodstream, avoiding immune detection and uptake by the reticuloendothelial system because of nanoparticle pegylation. Due to their size, the colloidal gold nanoparticles exit the circulatory system only at hyperpermeable tumor neovasculature sites; TNF then binds to and activates tumor cell TNF receptors, which may result in an increase in tumor cell apoptosis and a reduction in tumor cell proliferation. Compared to the administration of unbound TNF, colloidal gold-bound TNF may improve the efficacy and safety of TNF administration by delivering TNF specifically to tumor tissue.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62538</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C98288">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A colloidal mixture of nanoparticles consisting of small interfering RNA (siRNA) targeting the native eukaryotic translation initiation factor 5A (eIF5A), plasmids expressing a pro-apoptotic mutant of elF5A under the control of a B-cell specific promoter (B29), and a synthetic cationic polymer polyethylenimine (PEI) as a delivery vehicle, with potential antineoplastic activity. Upon administration, the siRNA component of SNS01-T suppresses elF5A expression, thereby interfering with translation of eIF5A and reducing levels of hypusinated elF5A in cancer cells. In turn, this inhibits activation of the transcription factor NF-kB and induces apoptosis. In addition, the B-cell specific plasmid component expresses an arginine substituted form of eIF5A, eIF5AK50R, which can not be hypusinated, thus leads to a selective induction of apoptosis in B-cells. The native unhypusinated form of eIF5A is pro-apoptotic and can be modified at the lysine residue, by deoxyhypusine synthase (DHS) and subsequently deoxyhypusine hydroxylase (DHH), to the anti-apoptotic hypusinated form which is associated with tumor cell growth and survival. The delivery vehicle protects the siRNA and plasmid from degradation.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C98288</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C187033">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C187033</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid nanoparticle preparation of archexin, a 20-mer antisense (AS) oligodeoxynucleotide (ODN) against the proto-oncogene Akt, with potential antineoplastic activity. Upon administration of AS ODN WGI-0301, archexin binds to Akt-1 mRNA, inhibiting translation of the transcript. Suppression of Akt-1 expression may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt-mediated signaling. This may inhibit proliferation and induce apoptosis of tumor cells in which Akt-1 is overexpressed. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C179607">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C179607</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An immunomodulating agent and nanovaccine composed of the invariant natural killer T cell (iNKT) agonist, dendritic cell (DC) transactivator, and an alpha-galactosylceramide (a-GalCer) analog threitolceramide-6 (ThrCer6, IMM60) and immunogenic peptides derived from the tumor-associated antigen (TAA) New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) encapsulated within poly(lactic-co-glycolic acid) (PLGA) nanoparticles, with potential immunomodulating and antineoplastic activities. Upon administration of NY-ESO-1 peptides/ThrCer6-loaded nanoparticles PORT-3, ThrCer6 targets and binds to the T-cell receptor on iNKTs, thereby activating the iNKTs. The activated iNKTs activate DCs, resulting in the secretion of a large amount of pro-inflammatory cytokines. The NY-ESO-1 peptides are processed and presented by DCs. Altogether, this induces antigen-specific CD4 and CD8 T cell, and B cell responses, and leads to the induction of a cytotoxic T-lymphocyte (CTL)-mediated immune response against NY-ESO-1-expressing tumor cells. Encapsulating antigens and adjuvants together within the same biodegradable polymeric nanoparticle can enhance T cell responses. NY-ESO-1 is a cancer-testis antigen normally expressed in testicular germ cells and trophoblasts of the placenta and overexpressed in a variety of cancers.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C115108">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C115108</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid nanoparticle-based formulation consisting of small-interfering RNAs (siRNAs) directed against the oncogene c-Myc encapsulated in lipids with potential antineoplastic activity. Upon intravenous administration of MYC-targeting siRNA DCR-MYC, the lipid formulation promotes the uptake by tumor cells where the siRNAs moieties are subsequently released. The siRNAs bind to c-Myc mRNAs, which may result in the inhibition of translation and expression of the c-Myc protein and leads to growth inhibition for tumor cells that are overexpressing c-Myc. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C156739">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A radioconjugate composed of a tumor-selective fluorescent imaging agent containing silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, cyanine 5 (Cy5), and surrounded by polyethylene glycol (PEG) chains attached to cyclic arginine-glycine-aspartic acid-tyrosine) (cyclo-(Arg-Gly-Asp-Tyr; cRGDY) peptides (C' dots; Cornell prime dots; cRGDY-PEG-C' dots), and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon intradermal administration of the zirconium Zr 89 cRGDY PEG-Cy5-C' dots, the cRGDY moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of integrin-expressing tumor cells as well as the visualization of the distribution, uptake and removal within tumor tissues. The fluorescence imaging agent is used to visualize alphaVbeta3-expressing tumor cells and assess the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C156739</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C170753">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C170753</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A biodegradable, lyophilized lipid nanoparticle (LNP) encapsulating small interfering ribonucleic acid (siRNA) directed against glutathione S-transferase P (GSTP), with potential antineoplastic activity. Upon administration of LNP encapsulating GSTP siRNA NBF-006, the LNP formulation delivers the siRNA particles to the tumor cells where the GSTP siRNA targets and binds to GSTP mRNA. This results in the inhibition of the translation and expression of GSTP and may inhibit proliferation of KRAS-overexpressing tumor cells. GSTP, an enzyme overexpressed in many tumor cell types, is involved in modulating MAP kinase-related cell-signaling pathways.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C62312">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62312</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoscale hollow polymeric vessels that have the potential to be utilized to selectively deliver hydrophobic drugs to specific sites within individual cells.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C178132">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A vaccine consisting of a lipid nanoparticle (LNP) encapsulating a self-transcribing and replicating messenger RNA (mRNA) encoding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) prefusion spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon administration of the SARS-CoV-2 mRNA vaccine ARCT-021, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cells. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may activate both humoral and cellular immune responses, and may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C178132</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C179581">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A synthetic microRNA (miRNA) mimic of the endogenous tumor suppressor miR-193a-3p formulated in lipid nanoparticles (LNPs), with potential antineoplastic and immune-activating activities. Upon administration, miRNA-193a-3p mimic INT-1B3 targets tumor cells, binds to its target sequence in mRNA transcripts, which leads to translational repression or mRNA degradation. This inhibits protein expression encoded by that particular mRNA sequence. INT-1B3 is able to downregulate many oncogenic signaling pathways, such as the oncogenic PI3K/Akt and Ras/MAPK pathways, and upregulate the tumor suppressive PTEN pathway. INT-1B3 also modulates the expression of cyclin D1, Mcl-1, K-Ras, c-Kit and TIM-3. In addition, INT-1B3 is able to modulate the tumor microenvironment (TME) through inhibition of CD39/CD73 and by downregulating the adenosine-A2A receptor pathway. This leads to a decrease in immunosuppressive FoxP3/Lag3 regulatory T cells and monocytic myeloid-derived suppressor cells (mMDSCs), increases the maturation of dendritic cells (DCs) and induces a T cell-mediated anti-tumor immune response. Altogether, this may induce cell cycle arrest and  apoptosis, increase cell senescence, and decrease tumor cell proliferation, survival, migration and metastasis.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C179581</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C148511">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation consisting of polymeric micelles, composed of triblock copolymers, loaded with the bioactive hydrophobic irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38), with potential antineoplastic activity. Upon administration, nanoparticle SN-38-encapsulated micelle formulation IT141 diffuses into the tumor site and the SN-38 moiety binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication, and apoptosis. Compared to SN-38 alone, this formulation increases the water solubility of SN-38 and allows the delivery of higher doses of SN-38. IT-141 also has a much longer circulation time and reduces toxicity to normal, healthy tissues.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C148511</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C204942">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid nanoparticle (LNP) formulation encapsulating messenger RNA (mRNA) encoding the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (Cas9) protein and a single guide RNA targeting transthyretin (TTR), that may decrease serum TTR concentration. Upon administration of LNP encapsulating mRNA encoding Cas9 protein and TTR-targeting single guide RNA NTLA-2001, the LNP moiety binds to the plasma membrane of nearby cells and releases the Cas9 mRNA and the TTR-targeting single guide RNA into the cells. The mRNA is then translated by the cellular protein translation machinery to produce Cas9, which gene-edits the TTR gene in vivo, thereby lowering the levels of misfolded TTR in the blood. This may reduce the accumulation of misfolded TTR protein in the tissues.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C204942</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C95892">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A proprietary preparation of polymeric nanoparticles containing the second-generation taxane docetaxel, targeted to prostate-specific membrane antigen (PSMA), with antineoplastic activity. PSMA-targeted docetaxel nanoparticles BIND-014 carry docetaxel within a matrix of polylactic acid covered with a coating of polyethylene glycol; embedded on the surface of the polyethylene glycol coating are ligands targeted to PSMA. BIND-014 allows gradual release of docetaxel upon degradation of the polylactic acid, and the PEG encapsulation escapes the host immune response while PSMA ligands on the surface restrict the cytotoxic effect to PSMA-expressing cells. Docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. PSMA is a cell-surface antigen that is abundantly present on the surface of cancer cells and on the neovasculature that feeds a wide variety of tumor types.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C95892</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C105613">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C105613</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An orally available nanoparticle-based formulation containing the hydrochloride salt form of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. The formulation consists of an oil-in-water emulsion in which gemicitabine is solubilized in the excipient matrix containing a mixture of oil and (co)surfactants. Upon oral administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis. Further, dFdCDP inhibits ribonucleotide reductase and reduces the deoxynucleotide pool available for DNA synthesis. Compared to gemcitabine alone, the emulsion allows for increased oral bioavailability and decreases its susceptibility to deamination and deactivation by cytidine deaminase.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C204213">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C204213</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nano-engineered intraoperative system containing a liquid permeation enhancer (PE) and a patch composed of nanoparticles loaded with the inorganic platinum agent cisplatin, with potential antineoplastic and immunomodulating activities. Immediately following surgical tumor resection, the cisplatin nano-engineered intraoperative system PRV211 is applied intraoperatively; the PE is brushed onto the resected tumor bed and then the cisplatin patch is applied onto the same tumor site. Upon subsequent long-lasting and controlled release from the patch and penetration into the tumor bed, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells. Cisplatin may reach regional lymph nodes and may trigger anti-tumor immune responses. Administration of PRV211 may eliminate any remaining micro metastases or close margins that could not be fully resected while avoiding system circulation. This may prevent systemic side effect and cancer recurrence.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C204794">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An mRNA-based, personalized cancer vaccine consisting of total tumor RNA (TTRNA) derived from autologous tumor cells, formulated in DOTAP lipid nanoparticles, with potential immunostimulatory and antineoplastic activities. Upon administration of the autologous total tumor mRNA loaded liposome vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs). The expressed epitopes are then presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these tumor antigens.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C204794</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C62597">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62597</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A peptide vaccine, containing nanoparticles of cholesteryl hydrophobized pullulan (CHP) complexed with the tumor-associated antigen HER-2/neu (ErbB-2), with potential antineoplastic activity. Her-2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumors, including breast, ovarian, and gastric cancers. Vaccination with CHP-HER-2 peptide vaccine may stimulate the host immune system to mount a humoral as well as a cytotoxic T-cell response against tumor cells expressing the HER-2/neu antigen. This results in an inhibition of tumor cell proliferation and tumor cell death. The self-aggregating CHP, composed of a pullulan backbone and cholesterol branches, forms stable colloidal nanoparticles in water.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C150508">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle formulation containing the poorly water-soluble naturally-occurring flavonoid luteolin encapsulated within a water-soluble polymer, with potential anti-oxidant, anti-inflammatory, apoptosis-inducing and chemopreventive activities. Upon administration of the polymer-encapsulated luteolin nanoparticle, luteolin scavenges free radicals, protects cells from reactive oxygen species (ROS)-induced damage and induces direct tumor cell cycle arrest and apoptosis in tumor cells. This inhibits tumor cell proliferation and suppresses metastasis. Compared to luteolin alone, encapsulation increases the delivery of luteolin to the tumor cells by protecting the drug against clearance and degradation, increases blood circulation time and enhances delivery into the tumor through the leaky vasculature.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C150508</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C62598">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A peptide cancer vaccine containing nanoparticles of cholesteryl hydrophobized pullulan (CHP) complexed with the cancer-testis antigen NY-ESO-1 protein, with potential immunostimulating and antineoplastic activities.  Upon administration, CHP-NY-ESO-1 peptide vaccine IMF-001 may stimulate the host immune system to mount a humoral and cytotoxic T-cell response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. The self-aggregating CHP, composed of a pullulan backbone and cholesterol branches, forms stable colloidal nanoparticles in water. NY-ESO-1, an antigen found in normal testis, is upregulated in various cancers, including bladder, breast, hepatocellular, melanoma, and prostate cancers.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C62598</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C82691">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C82691</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >An orally bioavailable nanoparticle albumin-bound inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AB-010 selectively binds to Hsp90, inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This agent may inhibit the growth of a wide variety of cancer cell types; the incorporation of albumin into its formulation may facilitate its endothelial transcytosis through the gp60-regulated albumin transport pathway. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding and degradation of many oncogenic signaling proteins.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C48203">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A complex consisting of a therapeutic entity coupled to a nanoparticle entity that has an external coating designed to deliver the therapeutic to a precise location in the body.  This complex is useful because of the ability to deliver drugs in a controlled fashion to a specific site of interest. Conjugates such as this are also utilized as imaging and contrast agents for MRI and other imaging studies.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C48203</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C142137">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A proprietary formulation consisting of a lipid nanoparticle encapsulating a synthetic messenger RNA (mRNA) encoding the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), with potential immunomodulatory and antitumor activities. Although the mechanism of action has not been completely characterized, following intratumoral injection of lipid nanoparticle encapsulated OX40L mRNA-2416, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the OX40L mRNA into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes. Altogether, this may enhance an immune response that promotes the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T cells.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C142137</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C126800">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C126800</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A lipid-based nanoparticle formulation composed of liposomes encapsulating a small oligonucleotide encoding a small activating RNA (saRNA) targeting the CCAAT enhancer binding protein alpha (CEBPA; C/EBP-a) gene, with potential antineoplastic activity. Although the exact mechanism of action through which saRNAs exert their effect(s) is still largely being investigated, it appears that, upon administration, the CEBPA-targeting saRNA MTL-CEBPA liposome targets and binds to a specific DNA regulatory target region, most likely the promoter region, for the CEBPA gene. This restores CEBPA gene transcription, and increases both CEBPA mRNA levels and protein expression. This in turn activates the expression of tumor suppressor genes and may halt proliferation of susceptible tumor cells. Specifically, upregulation of CEBPA in liver cells abrogates liver cancer cell proliferation, thereby prevents liver failure and normalizes liver function. CEBPA, a transcription factor that plays a key role in the regulation of the expression of genes with many functions, including those involved in cellular proliferation, metastasis and normal hepatocyte function, is found in many tissues, including liver cells, adipose tissue and myeloid cells. CEBPA is downregulated in certain types of cancer cells, such as liver cancer cells. saRNA is a short, double-stranded RNA that is structurally related to siRNAs; saRNA is most likely to bind to a target site on the promoter of the CEBPA gene and upregulates its gene expression.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C169048">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C169048</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A contrast agent formulation composed of a polymeric core containing the paramagnetic contrast agent manganese chloride tetrahydrate (MnCl2 4H2O), in which the Mn2+ ions are chelated to phosphonate groups, and covered with a coating layer of covalently attached polyetyleneglycol (PEG)-polymers, that can potentially be used as a contrast enhancer during magnetic resonance imaging (MRI). Upon intravenous administration of the nanoparticle-based manganese-containing contrast agent SN132D, the nanoparticles enhance absorption of the poorly absorbable contrast agent manganese, and selectively accumulates in the tumor microenvironment (TME). Due to the retention of manganese in the TME and its paramagnetic properties, this contrast agent enhances the visualization and detection of tumor cells during MRI.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C180692">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C180692</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A micelle nanoparticle formulation composed of the Toll-Like receptor 7 (TLR7) agonist phospholipid conjugate 1v270 encapsulated within 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)-polyethylene glycol (PEG)-2000, with potential immunostimulating activity. Upon intravenous administration of the nanoparticles encapsulating TLR7 agonist 1v270 MBS8, the TLR7 agonist targets, binds to and activates TLR7, thereby stimulating dendritic cells (DCs) and neutrophils, and enhancing natural killer cell (NK) cytotoxicity. This activation results in the production of pro-inflammatory cytokines, including interferon alpha. MBS8 may activate cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses leading to tumor cell lysis. In addition, MBS8 is able to stimulate immune memory T-cells to further recognize and eliminate cancer cells. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and the activation of innate immunity. The micelle formulation was engineered to reduce systemic cytokine production which may lower systemic toxicity. production which may lower systemic toxicity.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C124053">
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C124053</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based formulation containing the alkyl ester of bendamustine, a bifunctional mechlorethamine derivative, encapsulated in human serum albumin (HSA), with potential alkylating and antineoplastic activities. Upon administration of the alkyl ester bendamustine-containing nanoparticle formulation RXDX-107, the nanoparticle formulation permits high concentrations of the alkyl ester of bendamustine be localized at the tumor site. The modified bendamustine alkylates and crosslinks macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C200369">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C200369</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A radioconjugate comprised of the microRNA-10b (miR-10b)-inhibitor TTX-MC138, which consists of an anti-miR10b antagomir conjugated to ultrasmall iron oxide nanoparticles, chelated with 1,4,7-triazacyclononane,1-glutaric acid-4,7 acetic acid (NODAGA) and radiolabeled with the radiotracer copper Cu 64, that may be used as an imaging agent for miR-10b-overexpressing tumor cells upon positron emission tomography (PET)-magnetic resonance imaging (PET-MRI). Upon administration of copper Cu 64 NODAGA-TTX-MC138, the TTX-MC138 moiety targets and binds to miR-10b inside tumor cells. This allows for visualization of miR-10b-overexpressing tumor cells upon imaging with PET-MRI. miR-10b, a mRNA that is highly expressed in a variety of metastatic tumor cells, plays a key role in tumor cell migration, invasion and metastasis.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C98280">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A suspension of nanoparticles containing inert inorganic hafnium oxide (HfO2) crystals with potential antineoplastic activity. Upon injection of NBTXR3 in the tumor, the hafnium oxide-containing nanoparticles accumulate into the tumor cells. Subsequent application of radiation beams to the tumor tissue causes HfO2 particles to emit huge amounts of electrons. This results in the formation of free radicals within the tumor cells, which in turn causes targeted destruction of the cancer cells. Compared to standard radiotherapy, because of the inert nature of NBTXR3, this agent emits electrons only during its exposure to radiation which improves radiotherapy efficiency.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C98280</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C82676">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A liposomal dispersion formulated with the semisynthetic camptothecin analogue irinotecan, provided as the hydrochloride trihydrate form, which is encapsulated and entrapped within liposomes in a gelated or precipitated state as the irinotecan sucrose octasulfate (sucrosulfate) salt form, with potential antineoplastic activity. Upon administration of the liposomes containing irinotecan sucrosulfate, irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. During the S-phase, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell, extends the circulation of irinotecan, and prolongs the duration of active therapy at the site of tumor to inhibit tumor growth.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C82676</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C113175">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Polymeric micellar nanoparticles containing diaminocyclohexane platinum (DACH-platin or DACH-Pt) with potential antineoplastic activity. DACH-platin micelle NC-4016 is prepared through the formation of a polymer-metal complex between DACH-platin and the polyethylene glycol-poly (glutamic acid) block copolymer, PEG-P(Glu). DACH-platin, an active metabolite of the platinum-based antineoplastic agent oxaliplatin, is highly hydrophobic and toxic when administered systemically. The use of polymeric micelles incorporating DACH-platin may both increase cell permeability and enhance the retention of the agent. This allows an extended half-life in the blood circulation and a selective and high accumulation of DACH-platin at tumor sites. This results in increased anticancer efficacy while reducing side effects due to DACH-platin toxicity. Upon intravenous administration and internalization by tumor cells, DACH-platin binds to and causes both inter- and intra-strand cross-links in DNA, forming platinum adducts and triggering tumor cell apoptosis.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C113175</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
  </owl:Class>
  <owl:Class rdf:ID="C118648">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C118648</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A nanoparticle-based suspension containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intraperitoneal administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division. The nanoparticle-based formulation is devoid of toxic solvents, such as cremophor; therefore, this agent has fewer side effects than the standard, solvent-based paclitaxel formulation.</rdfs:comment>
  </owl:Class>
  <owl:Class rdf:ID="C157771">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A spherical nucleic acid (SN)-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, cavrotolimod targets and is able to enter various immune cells, including monocytes/macrophages, plasmacytoid dendritic cells (pDCs), natural killer (NK) cells and B cells, through endocytosis. Within the endosome, it binds to and activates TLR9. TLR9 activation induces immune signaling pathways and activates various immune cells, including B-cells, pDCs, NKs, and induces both the production of T-helper 1 cells (Th1) and a Th1-mediated immune response as well as a cytotoxic T-lymphocyte (CTL)-based immune response against tumor cells. This results in an inhibition of tumor cell proliferation. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate and adaptive immune responses. The SNA is a dense, radial arrangement of nucleic acids (DNA) on the surface of liposomal nanoparticles, providing a 3D-construct, that has a high cellular uptake and an increased presentation of the DNA for TLR9 agonism. It also protects against breakdown by nucleases and increases the half-life of the construct compared to linear oligonucleotides that are not in SNA format.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C157771</rdfs:label>
  </owl:Class>
  <owl:Class rdf:ID="C210897">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C210897</rdfs:label>
    <rdfs:subClassOf rdf:resource="#Term"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >A formulation consisting of lipid nanoparticle (LNP)-encapsulated small interfering ribonucleic acid (siRNA) targeting beta-catenin, with potential antineoplastic activity. Upon administration of LNP encapsulating beta-catenin siRNA ALN-BCAT, the LNP formulation delivers the siRNA particles to the tumor cells where the beta-catenin siRNA targets and binds to beta-catenin mRNA. This results in the inhibition of the translation and expression of beta-catenin. This disrupts beta-catenin-dependent oncogenic signaling and prevents the transcription of Wnt target genes that regulate the proliferation, migration, invasion, and the metastatic potential of tumor cells, as well as genes regulating the immunosuppression of the tumor microenvironment (TME). Dysregulation of the Wnt/beta-catenin signaling pathway is found in a variety of tumors and drives oncogenesis.</rdfs:comment>
  </owl:Class>
  <owl:ObjectProperty rdf:ID="semanticType">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >semanticType</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Tipo semntico del trmino. Una instancia requerida de la clase abstracta SemanticType. Puede ser mltiple.</rdfs:comment>
    <rdfs:domain>
      <owl:Class>
        <owl:unionOf rdf:parseType="Collection">
          <rdf:Description rdf:about="http://www.w3.org/2002/07/owl#Thing"/>
          <owl:Class rdf:about="#Term"/>
        </owl:unionOf>
      </owl:Class>
    </rdfs:domain>
    <rdfs:range rdf:resource="#SemanticType"/>
  </owl:ObjectProperty>
  <owl:FunctionalProperty rdf:ID="name">
    <rdfs:domain>
      <owl:Class>
        <owl:unionOf rdf:parseType="Collection">
          <rdf:Description rdf:about="http://www.w3.org/2002/07/owl#Thing"/>
          <owl:Class rdf:about="#Thing"/>
        </owl:unionOf>
      </owl:Class>
    </rdfs:domain>
    <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#string"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >name</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >El nombre del trmino. Si Display Name tiene un valor ser ese, en caso contrario se usar el primer sinnimo de Synonym.

O el nombre de la instancia de SemanticType</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#DatatypeProperty"/>
  </owl:FunctionalProperty>
  <C198655 rdf:about="proyectoTFG_Class10096">
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class33">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Indicator, Reagent, or Diagnostic Aid</name>
      </SemanticType>
    </semanticType>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Copper 64 Cu-labeled Macrophage-targeted Nanoparticle</name>
  </C198655>
  <C126800 rdf:about="proyectoTFG_Class14">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >CEBPA-targeting saRNA MTL-CEBPA Liposome</name>
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class39">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Pharmacologic Substance</name>
      </SemanticType>
    </semanticType>
  </C126800>
  <C173054 rdf:about="proyectoTFG_Class10058">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >SARS-CoV-2 SP modRNA LNP vaccine BNT162a1</name>
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class36">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Nucleic Acid, Nucleoside, or Nucleotide</name>
      </SemanticType>
    </semanticType>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C173054>
  <C91708 rdf:about="proyectoTFG_Class10142">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Quaratusugene Ozeplasmid</name>
  </C91708>
  <C189804 rdf:about="proyectoTFG_Class10088">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Elasomeran/Davesomeran</name>
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C189804>
  <C71696 rdf:about="proyectoTFG_Class10130">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle Albumin-Bound Docetaxel</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C71696>
  <C160867 rdf:about="proyectoTFG_Class10044">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C160867>
  <C180409 rdf:about="proyectoTFG_Class10076">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >delta9-Tetrahydrocannabinol/Cannabidiol Combination Agent</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C180409>
  <C189803 rdf:about="proyectoTFG_Class10087">
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Elasomeran/Imelasomeran</name>
  </C189803>
  <C121214 rdf:about="proyectoTFG_Class10">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanocell-encapsulated miR-16-based microRNA Mimic</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C121214>
  <C113175 rdf:about="proyectoTFG_Class1">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >DACH-Platin Micelle NC-4016</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C113175>
  <C62358 rdf:about="proyectoTFG_Class10120">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Gadolinium-Chelate</name>
    <semanticType rdf:resource="proyectoTFG_Class33"/>
  </C62358>
  <C98280 rdf:about="proyectoTFG_Class10145">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Hafnium Oxide-containing Nanoparticles NBTXR3</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C98280>
  <C121961 rdf:about="proyectoTFG_Class12">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Docetaxel Nanoparticle CPC634</name>
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class37">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Organic Chemical</name>
      </SemanticType>
    </semanticType>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C121961>
  <C169048 rdf:about="proyectoTFG_Class10051">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle-based Manganese-containing Contrast Agent SN132D</name>
    <semanticType rdf:resource="proyectoTFG_Class33"/>
  </C169048>
  <C179638 rdf:about="proyectoTFG_Class10073">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Ribocytokine IL-2 BNT153</name>
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class26">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Amino Acid, Peptide, or Protein</name>
      </SemanticType>
    </semanticType>
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class32">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Immunologic Factor</name>
      </SemanticType>
    </semanticType>
  </C179638>
  <C190750 rdf:about="proyectoTFG_Class10094">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Davesomeran</name>
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C190750>
  <C90534 rdf:about="proyectoTFG_Class10139">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Protein Stabilized Liposomal Docetaxel Nanoparticles</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C90534>
  <C62311 rdf:about="proyectoTFG_Class10118">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle-Mediated Drug Delivery</name>
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class25">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Activity</name>
      </SemanticType>
    </semanticType>
  </C62311>
  <C98288 rdf:about="proyectoTFG_Class10146">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >SNS01-T Nanoparticles</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C98288>
  <C179685 rdf:about="proyectoTFG_Class10075">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Detalimogene Voraplasmid</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C179685>
  <C180692 rdf:about="proyectoTFG_Class10078">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticles Encapsulating TLR7 Agonist 1v270 MBS8</name>
  </C180692>
  <C189973 rdf:about="proyectoTFG_Class10090">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Tozinameran/Famtozinameran</name>
  </C189973>
  <C190391 rdf:about="proyectoTFG_Class10092">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 JCXH-211</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C190391>
  <C48203 rdf:about="proyectoTFG_Class10114">
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class30">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Conceptual Entity</name>
      </SemanticType>
    </semanticType>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle-targeted Drug</name>
  </C48203>
  <C178643 rdf:about="proyectoTFG_Class10068">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle SN-38-encapsulated Micelle Formulation SNB-101</name>
  </C178643>
  <C78450 rdf:about="proyectoTFG_Class10132">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01</name>
  </C78450>
  <C159408 rdf:about="proyectoTFG_Class10042">
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class41">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Therapeutic or Preventive Procedure</name>
      </SemanticType>
    </semanticType>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Atezolizumab/Nab-paclitaxel Regimen</name>
  </C159408>
  <C162186 rdf:about="proyectoTFG_Class10045">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >mRNA-derived KRAS-targeted Vaccine V941</name>
  </C162186>
  <C129651 rdf:about="proyectoTFG_Class16">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Polysiloxane/Gadolinium Chelates-based Nanoparticles</name>
    <semanticType rdf:resource="proyectoTFG_Class33"/>
    <semanticType rdf:resource="proyectoTFG_Class37"/>
  </C129651>
  <C91087 rdf:about="proyectoTFG_Class10141">
    <semanticType rdf:resource="proyectoTFG_Class37"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Docetaxel-PNP</name>
  </C91087>
  <C137951 rdf:about="proyectoTFG_Class22">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Belzupacap Sarotalocan</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C137951>
  <C201245 rdf:about="proyectoTFG_Class10099">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Bioadhesive Nanoparticles-encapsulating Avobenzone/Octocrylene Plus Diosmin/Ferulic Acid/Cytisine/Trans-resveratrol Sunscreen</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C201245>
  <C148280 rdf:about="proyectoTFG_Class10027">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >MOF Compound RiMO-301</name>
  </C148280>
  <C211533 rdf:about="proyectoTFG_Class10110">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanocurcumin</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C211533>
  <C82391 rdf:about="proyectoTFG_Class10133">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Anti-KSP/Anti-VEGF siRNAs ALN-VSP02</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C82391>
  <C62375 rdf:about="proyectoTFG_Class10122">
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class29">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Classification</name>
      </SemanticType>
    </semanticType>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoshell</name>
  </C62375>
  <C38140 rdf:about="proyectoTFG_Class10112">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Ferumoxtran-10</name>
    <semanticType rdf:resource="proyectoTFG_Class33"/>
  </C38140>
  <C170743 rdf:about="proyectoTFG_Class10052">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Liposomal Bcl-2 Antisense Oligonucleotide BP1002</name>
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C170743>
  <C187116 rdf:about="proyectoTFG_Class10085">
    <semanticType rdf:resource="proyectoTFG_Class37"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Polymeric Nanoparticle-conjugated Camptothecin DAN-222</name>
  </C187116>
  <C117733 rdf:about="proyectoTFG_Class8">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Electrokinetically Modified Water</name>
  </C117733>
  <C210897 rdf:about="proyectoTFG_Class10109">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle Encapsulating Beta-catenin siRNA ALN-BCAT</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C210897>
  <C62367 rdf:about="proyectoTFG_Class10121">
    <semanticType rdf:resource="proyectoTFG_Class29"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanobomb</name>
  </C62367>
  <C165263 rdf:about="proyectoTFG_Class10047">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Docetaxel Polymeric Micelles</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C165263>
  <C200091 rdf:about="proyectoTFG_Class10097">
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class38">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Organization</name>
      </SemanticType>
    </semanticType>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >ANP Technologies</name>
  </C200091>
  <C172736 rdf:about="proyectoTFG_Class10054">
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Moderna COVID-19 Vaccine</name>
  </C172736>
  <C184380 rdf:about="proyectoTFG_Class10080">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Anti-TGF-beta 1/Anti-COX-2 siRNAs STP707</name>
  </C184380>
  <C153425 rdf:about="proyectoTFG_Class10034">
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class34">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Inorganic Chemical</name>
      </SemanticType>
    </semanticType>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Platinum Acetylacetonate-Titanium Dioxide Nanoparticles</name>
  </C153425>
  <C118648 rdf:about="proyectoTFG_Class9">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle-based Paclitaxel Suspension</name>
  </C118648>
  <C179620 rdf:about="proyectoTFG_Class10072">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >mRNA-encoded Anti-Claudin18.2 Monoclonal Antibody BNT141</name>
  </C179620>
  <C178132 rdf:about="proyectoTFG_Class10067">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >SARS-CoV-2 mRNA Vaccine ARCT-021</name>
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C178132>
  <C175469 rdf:about="proyectoTFG_Class10064">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Fenretinide Phospholipid Suspension ST-001</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C175469>
  <C62308 rdf:about="proyectoTFG_Class10117">
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class40">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Physical Object</name>
      </SemanticType>
    </semanticType>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle</name>
  </C62308>
  <C131368 rdf:about="proyectoTFG_Class18">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Spherical Nucleic Acid Nanoparticle NU-0129</name>
  </C131368>
  <C62598 rdf:about="proyectoTFG_Class10127">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >CHP-NY-ESO-1 Peptide Vaccine IMF-001</name>
    <semanticType rdf:resource="proyectoTFG_Class32"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C62598>
  <C187083 rdf:about="proyectoTFG_Class10084">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle Formulation CPI-300</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C187083>
  <C173851 rdf:about="proyectoTFG_Class10061">
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Zorecimeran</name>
  </C173851>
  <C115104 rdf:about="proyectoTFG_Class2">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Fluorescent cRGDY PEG-Cy5.5 C Dots</name>
    <semanticType rdf:resource="proyectoTFG_Class33"/>
  </C115104>
  <C172755 rdf:about="proyectoTFG_Class10055">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >SARS-CoV-2 rS Nanoparticle Vaccine NVX-CoV2373</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C172755>
  <C157247 rdf:about="proyectoTFG_Class10038">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C157247>
  <C111688 rdf:about="proyectoTFG_Class0">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101</name>
    <semanticType rdf:resource="proyectoTFG_Class32"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C111688>
  <C187021 rdf:about="proyectoTFG_Class10082">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Pasifolate Exatecan</name>
  </C187021>
  <C174128 rdf:about="proyectoTFG_Class10063">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Multi-antigen-directed Autologous T-cells NEXI-002</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class27">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Cell</name>
      </SemanticType>
    </semanticType>
  </C174128>
  <C179581 rdf:about="proyectoTFG_Class10070">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >miRNA 193a-3p Mimic INT-1B3</name>
  </C179581>
  <C115986 rdf:about="proyectoTFG_Class4">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Carbon Nanoparticle-based Formulation</name>
    <semanticType rdf:resource="proyectoTFG_Class33"/>
  </C115986>
  <C204794 rdf:about="proyectoTFG_Class10105">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Autologous Total Tumor mRNA Loaded Liposome Vaccine</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C204794>
  <C62388 rdf:about="proyectoTFG_Class10124">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanosphere</name>
    <semanticType rdf:resource="proyectoTFG_Class29"/>
  </C62388>
  <C166389 rdf:about="proyectoTFG_Class10049">
    <semanticType rdf:resource="proyectoTFG_Class41"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Atezolizumab/Carboplatin/Nab-paclitaxel Regimen</name>
  </C166389>
  <C131825 rdf:about="proyectoTFG_Class20">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C131825>
  <C205639 rdf:about="proyectoTFG_Class10107">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 STX-001</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C205639>
  <C116869 rdf:about="proyectoTFG_Class6">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C116869>
  <C124053 rdf:about="proyectoTFG_Class13">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Bendamustine-containing Nanoparticle-based Formulation RXDX-107</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C124053>
  <C200369 rdf:about="proyectoTFG_Class10098">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Copper Cu 64 NODAGA-TTX-MC138</name>
    <semanticType rdf:resource="proyectoTFG_Class33"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C200369>
  <C62312 rdf:about="proyectoTFG_Class10119">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanocontainer</name>
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class35">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Manufactured Object</name>
      </SemanticType>
    </semanticType>
  </C62312>
  <C139003 rdf:about="proyectoTFG_Class10023">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Micellar Nanoparticle-encapsulated Epirubicin</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C139003>
  <C179639 rdf:about="proyectoTFG_Class10074">
    <semanticType rdf:resource="proyectoTFG_Class26"/>
    <semanticType rdf:resource="proyectoTFG_Class32"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Ribocytokine IL-7 BNT152</name>
  </C179639>
  <C170753 rdf:about="proyectoTFG_Class10053">
    <semanticType rdf:resource="proyectoTFG_Class26"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006</name>
  </C170753>
  <C180674 rdf:about="proyectoTFG_Class10077">
    <semanticType rdf:resource="proyectoTFG_Class26"/>
    <semanticType rdf:resource="proyectoTFG_Class32"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >CD122-selective IL-2/Anti-CD25 Antibody-like Fusion Protein ANV419</name>
  </C180674>
  <C116792 rdf:about="proyectoTFG_Class5">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Patisiran</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C116792>
  <C68566 rdf:about="proyectoTFG_Class10129">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >SPIO Nanoparticle</name>
    <semanticType rdf:resource="proyectoTFG_Class40"/>
  </C68566>
  <C121539 rdf:about="proyectoTFG_Class11">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Docetaxel-loaded Nanopharmaceutical CRLX301</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C121539>
  <C173056 rdf:about="proyectoTFG_Class10060">
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Pidacmeran</name>
  </C173056>
  <C88305 rdf:about="proyectoTFG_Class10138">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Quaternary Ammonium Polyethylenimine Nanoparticles</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C88305>
  <C179302 rdf:about="proyectoTFG_Class10069">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Epstein-Barr Virus gp350-ferritin Nanoparticle Vaccine with Saponin-based Adjuvant</name>
  </C179302>
  <C157499 rdf:about="proyectoTFG_Class10039">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoscale Coordination Polymer Nanoparticles CPI-100</name>
  </C157499>
  <C150508 rdf:about="proyectoTFG_Class10032">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Polymer-encapsulated Luteolin Nanoparticle</name>
  </C150508>
  <C148511 rdf:about="proyectoTFG_Class10028">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle SN-38-encapsulated Micelle Formulation IT-141</name>
  </C148511>
  <C158083 rdf:about="proyectoTFG_Class10041">
    <semanticType rdf:resource="proyectoTFG_Class26"/>
    <semanticType rdf:resource="proyectoTFG_Class32"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide</name>
  </C158083>
  <C48415 rdf:about="proyectoTFG_Class10115">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Paclitaxel-Loaded Polymeric Micelle</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C48415>
  <C162773 rdf:about="proyectoTFG_Class10046">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Submicron Particle Paclitaxel Sterile Suspension</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C162773>
  <C88264 rdf:about="proyectoTFG_Class10137">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >C-VISA BikDD:Liposome</name>
  </C88264>
  <C82676 rdf:about="proyectoTFG_Class10134">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Irinotecan Sucrosofate</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C82676>
  <C203653 rdf:about="proyectoTFG_Class10103">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle Encapsulated AChR Epitopes CNP-106</name>
  </C203653>
  <C115108 rdf:about="proyectoTFG_Class3">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >MYC-targeting siRNA DCR-MYC</name>
  </C115108>
  <C157771 rdf:about="proyectoTFG_Class10040">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Cavrotolimod</name>
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C157771>
  <C91074 rdf:about="proyectoTFG_Class10140">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C91074>
  <C147562 rdf:about="proyectoTFG_Class10026">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Synthetic Vaccine Particles-Rapamycin</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C147562>
  <C148522 rdf:about="proyectoTFG_Class10029">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >HAAH Lambda phage Vaccine SNS-301</name>
  </C148522>
  <C62597 rdf:about="proyectoTFG_Class10126">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >CHP-HER-2 Peptide Vaccine</name>
    <semanticType rdf:resource="proyectoTFG_Class32"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C62597>
  <C166169 rdf:about="proyectoTFG_Class10048">
    <semanticType rdf:resource="proyectoTFG_Class33"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C' Dots</name>
  </C166169>
  <C102875 rdf:about="proyectoTFG_Class23">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle-encapsulated Doxorubicin Hydrochloride</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C102875>
  <C148635 rdf:about="proyectoTFG_Class10031">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >PEOX-based Polymer Encapsulated Paclitaxel FID-007</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C148635>
  <C95892 rdf:about="proyectoTFG_Class10143">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >PSMA-targeted Docetaxel Nanoparticles BIND-014</name>
    <semanticType rdf:resource="proyectoTFG_Class37"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C95892>
  <C85476 rdf:about="proyectoTFG_Class10136">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Demplatin Pegraglumer</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C85476>
  <C146821 rdf:about="proyectoTFG_Class10025">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle Paclitaxel Ointment SOR007</name>
  </C146821>
  <C182103 rdf:about="proyectoTFG_Class10079">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle-encapsulated SARS-CoV-2 mRNA Vaccine PTX-COVID19-B</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C182103>
  <C190751 rdf:about="proyectoTFG_Class10095">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Famtozinameran</name>
  </C190751>
  <C189806 rdf:about="proyectoTFG_Class10089">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Riltozinameran/Tozinameran</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C189806>
  <C154569 rdf:about="proyectoTFG_Class10035">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Doxorubicin-loaded EGFR-targeting Nanocells</name>
  </C154569>
  <C187124 rdf:about="proyectoTFG_Class10086">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >mRNA-encoded Anti-CD3/Anti-CLDN6 Bispecific Antibody BNT142</name>
    <semanticType rdf:resource="proyectoTFG_Class26"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C187124>
  <C179607 rdf:about="proyectoTFG_Class10071">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >NY-ESO-1 Peptides/Threitolceramide-6-loaded Nanoparticles PORT-3</name>
    <semanticType rdf:resource="proyectoTFG_Class32"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C179607>
  <C2688 rdf:about="proyectoTFG_Class10111">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nab-paclitaxel</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C2688>
  <C131213 rdf:about="proyectoTFG_Class17">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nab-paclitaxel/Rituximab-coated Nanoparticle AR160</name>
  </C131213>
  <C142137 rdf:about="proyectoTFG_Class10024">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle Encapsulated OX40L mRNA-2416</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C142137>
  <C160824 rdf:about="proyectoTFG_Class10043">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >NanoTherm Therapy</name>
    <semanticType rdf:resource="proyectoTFG_Class41"/>
  </C160824>
  <C208344 rdf:about="proyectoTFG_Class10108">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >MicroRNA-10b Antagomir-Iron Oxide/Dextran-based Nanoparticle TTX-MC138</name>
  </C208344>
  <C39438 rdf:about="proyectoTFG_Class10113">
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class31">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Health Care Related Organization</name>
      </SemanticType>
    </semanticType>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Jonsson Comprehensive Cancer Center</name>
  </C39438>
  <C62384 rdf:about="proyectoTFG_Class10123">
    <semanticType>
      <SemanticType rdf:about="proyectoTFG_Class28">
        <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
        >Chemical Viewed Structurally</name>
      </SemanticType>
    </semanticType>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Liposome Vesicle</name>
  </C62384>
  <C187033 rdf:about="proyectoTFG_Class10083">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Akt-1 Antisense Oligonucleotide WGI-0301</name>
  </C187033>
  <C190153 rdf:about="proyectoTFG_Class10091">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle Encapsulated MYC-targeting mRNA-based Agent OTX-2002</name>
  </C190153>
  <C201982 rdf:about="proyectoTFG_Class10100">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Dual-activating Polyvalent STING Agonist ONM-501</name>
  </C201982>
  <C204942 rdf:about="proyectoTFG_Class10106">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle Encapsulating mRNA Encoding Cas9 Protein and TTR-targeting Single Guide RNA NTLA-2001</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C204942>
  <C173055 rdf:about="proyectoTFG_Class10059">
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Tozinameran</name>
  </C173055>
  <C173879 rdf:about="proyectoTFG_Class10062">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Encapsulated Rapamycin</name>
  </C173879>
  <C190739 rdf:about="proyectoTFG_Class10093">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nab-paclitaxel/Danburstotug Complex AP160</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C190739>
  <C150717 rdf:about="proyectoTFG_Class10033">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Panobinostat Nanoparticle Formulation MTX110</name>
  </C150717>
  <C185869 rdf:about="proyectoTFG_Class10081">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C185869>
  <C148531 rdf:about="proyectoTFG_Class10030">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Paclitaxel Polymeric Micelle Formulation NANT-008</name>
  </C148531>
  <C66943 rdf:about="proyectoTFG_Class10128">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Vinorelbine Tartrate Emulsion</name>
  </C66943>
  <C82691 rdf:about="proyectoTFG_Class10135">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Hsp90 Inhibitor AB-010</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C82691>
  <C136981 rdf:about="proyectoTFG_Class21">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C136981>
  <C204213 rdf:about="proyectoTFG_Class10104">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Cisplatin Nano-engineered Intraoperative System PRV211</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C204213>
  <C175941 rdf:about="proyectoTFG_Class10065">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Cotsiranib</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C175941>
  <C156739 rdf:about="proyectoTFG_Class10036">
    <semanticType rdf:resource="proyectoTFG_Class33"/>
    <semanticType rdf:resource="proyectoTFG_Class26"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Zirconium Zr 89-DFO-cRGDY PEG-Cy5-C' Dots</name>
  </C156739>
  <C202248 rdf:about="proyectoTFG_Class10101">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Lipid Nanoparticle Encapsulated mRNA Encoding Human Single-chain IL-12 ABO2011</name>
  </C202248>
  <C202862 rdf:about="proyectoTFG_Class10102">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >PLZ4-coated Paclitaxel-loaded Micelle Formulation</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C202862>
  <C173020 rdf:about="proyectoTFG_Class10056">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >SARS-CoV-2 mRNA Vaccine BNT162</name>
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C173020>
  <C131434 rdf:about="proyectoTFG_Class19">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Ceramide Nanoliposome</name>
  </C131434>
  <C156926 rdf:about="proyectoTFG_Class10037">
    <semanticType rdf:resource="proyectoTFG_Class32"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Sapecmeran Autogene</name>
  </C156926>
  <C62538 rdf:about="proyectoTFG_Class10125">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Colloidal Gold-Bound Tumor Necrosis Factor</name>
    <semanticType rdf:resource="proyectoTFG_Class26"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C62538>
  <C105613 rdf:about="proyectoTFG_Class43">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Gemcitabine Hydrochloride Emulsion</name>
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C105613>
  <C116890 rdf:about="proyectoTFG_Class7">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C116890>
  <C49178 rdf:about="proyectoTFG_Class10116">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector IMNN-001</name>
  </C49178>
  <C173052 rdf:about="proyectoTFG_Class10057">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Abdavomeran</name>
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C173052>
  <C177085 rdf:about="proyectoTFG_Class10066">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Ganulameran</name>
    <semanticType rdf:resource="proyectoTFG_Class36"/>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C177085>
  <C74065 rdf:about="proyectoTFG_Class10131">
    <semanticType rdf:resource="proyectoTFG_Class39"/>
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Sirolimus Albumin-bound Nanoparticles</name>
  </C74065>
  <C96037 rdf:about="proyectoTFG_Class10144">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Paclitaxel Injection Concentrate for Nanodispersion</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C96037>
  <C167334 rdf:about="proyectoTFG_Class10050">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Pegylated SN-38 Conjugate PLX038</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C167334>
  <C128132 rdf:about="proyectoTFG_Class15">
    <name rdf:datatype="http://www.w3.org/2001/XMLSchema#string"
    >Iodine I 124-cRGDY-PEG-C Dots</name>
    <semanticType rdf:resource="proyectoTFG_Class39"/>
  </C128132>
</rdf:RDF>

<!-- Created with Protege (with OWL Plugin 3.4.8, Build 629)  http://protege.stanford.edu -->
